PROTOC OL: SHP6 81-101
TITLE : A Randomized, Double- blind, Placebo -controlled, Phase 1 Study to 
Assess the Saf ety, Tolerabili ty, and Pharmacokinetics of Ascending, 
Subcutaneous, Single and Multiple Doses of SHP681 ( GLP- 2 analo g-Fc 
fusion) in Healt hy Adult S ubjects
DRUG: SHP681 (Glucagon- like peptid e-2 (GLP-2) analog-Fc fusion protein)
IND: 139424
EUDRACT NO.: Non-EUDRACT
SPONSOR: Shire Human Genetic Therapies, Inc. (Shire)
300 Shire Way , Lexington, MA 02421 USA 
PRINCIPAL/
COORDINATING
INVESTIGATOR :
PROTOCOL Original Protocol: 29 Oct 2018
HISTORY: Amendment 1: 11 Feb 2019
Amendment 2: 10 May  2019
Amendment 3: 08 Oct 2019
Amendment 4: 19 Nov 2019
This document contains confidential and proprietary information of Shire and is disclosed 
pursuant to confidentiality and no n-disclosure obligations. This information should be used 
solel y for the purposes for which it was provided and should not be copied, shared with, or 
disclosed to any thirdpartywithout the express written consent of Shir e.
For non-commercial use only
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 4
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Protocol
Amendments
Summary ofChange(s) Since Last Version ofApproved Protocol
Amendment Number
4Amendment Date
19 Nov 2019Global/Country/Site
Specific
Glo
bal
Description ofChange Section(s) Affected byChange
Abnorm algallbladder w all thickness and gallbladder diameter which were 
noted in the subject above may be related to pharmacodynamic effects of 
SHP681. To characterize changes in the biliary tree caused by SHP681, 
abdominal ultrasound will be obtained during screening and at the end of 
treatment in the final MAD cohort.Table 7 , Table 10 , Table 11 ,
Section 3.1.2 , Section 7.2.2.10 , 
Section 9.9
Removed the analysis of crypt depth as this data was not collected. Synopsis ,Section 9.10
Clarified that PK samples drawn beyond Day 2 cannot deviate by more 
than ±10% of the specified time from the first dose.Table 7 , Table 9 , Table 10 , 
Section 7.1, Section 7.2.3
Deleted the Day 43 abbreviated physical exam to be consistent with MAD 
cohorts 1 -5 and overall schedule of assessments for MAD cohort 6.Table 7
The visit windows were updated to allow  for subject flexibility. Table 7 , Table 9 , Table 10
Minor editorial changes a nd corrections to typographical errors (w hich do 
not modify content and/or intent of the original document) were made.Throughout the protocol
See Appendix 1 for protocol histor y, including all amendments.
For non-commercial use only
Shire CONFIDENTIAL Page 5
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
EMERGENCY CON TACT INFORM ATION
In the event of a serious adverse event (SAE), the investigator must fax or e-mail the Shire 
Clinical Study Serious Adverse Event and Non-serious AEs Required by the Protocol Form 
within 24 hours to the Shire Global Drug Saf ety Department. Applicable fax numbers and e-mail 
address (drugsafet y@shire.com) can be found on the form (sent under separate cover). A cop y of 
this form must also be sent to the contract research organization (CRO)/Shire medical monitor by
faxor e-mail using the details below.
Forprotocol - or safety-related issues, the investigator must contact the Shire 
medical mon itor:
Telephone (24 -hour coverage ):
 
For non-commercial use only
Shire CONFIDENTIAL Page 6
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
ADDITIONAL CONTACT I NFORMATION
Incase ofanyother issues,including non-safety- related issues orifthemedica l
monitor is unable to be reached, the investigator must contact the Shire Study Lead:
Telephone:
 (business hours)
 (24-hour coverage) 
If unavailable, please contact:
Telephone: 
 (business hours)
 (24-hour coverage)
For non-commercial use only
Shire CONFIDENTIAL Page 7
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
PRODUCT QUALITY COMP LAINTS
Investigators are required to report investigational product quality c omplaints to Shire within 
24hours. This includes anyinstances wherein the quality or performance of a Shire product 
(marketed or investigational) does not meet expectations (eg, inadequate or faulty closure, 
product contamination) or that the product did not meet the specifications defined in the 
application for the product (eg, wrong product such that the label and contents are different 
products). For instructions on reporting AEs related to produc t complain ts, see Section 8.
Please use the information below as applicable to report the Product Quality Complaint:
Origin of Product Quality Complaint E
-mail Address
North and South America
European Union and Rest of World
Telephone numbers (provided for reference if needed):
Shire, Lexington, MA (USA)
For non-commercial use only
Shire CONFIDENTIAL Page 8
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
TABLE OF CONTENTS
PROTOCOL SIGNATURE PAGE ..................................................................................................2
SUMMARY OF CHANGES FROM PREVIOUS VERSI O
N........................................................3
EMERGENCY CON TACT INFOR MATION ................................................................................5
ADDITIONAL CONTACT I NFORMATION ................................................................................6
PRODUCT QUALITY COMP LAINTS ..........................................................................................7
TABLE OF CONTENTS .................................................................................................................8
LIST OF TABLES .........................................................................................................................11
LIST OF FIGURES .......................................................................................................................11
ABBREVIAT IONS .......................................................................................................................12
STUDY SYNOPSI S
......................................................................................................................13
STUDY SCHEDUL E(S)
...............................................................................................................20
1. BACKGROUND INFORMATI ON......................................................................................36
1.1 Indication and Current Treatment Options ..................................................................36
1.2 Product Background .....................................................................................................37
1.2.1 Preclinical Information ......................................................................................37
1.2.2 Clinical I nformation ...........................................................................................37
1.3 Risk/Benefit and Ethical Assessment ..........................................................................37
2. STUDY OBJECTIVES AND PURPOSE .............................................................................38
2.1 Rationale for the Study ................................................................................................38
2.2 Study  Objectives ..........................................................................................................38
2.2.1 Primary  Objectives .............................................................................................38
2.2.2 Secondary  Objectives .........................................................................................38
2.2.3 Exploratory  
Objectives ......................................................................................38
3. STUDY DESIGN ...................................................................................................................39
3.1 Study  Design and Flow Chart ......................................................................................39
3.1.1 Dose
selection, rationale andadministration ......................................................40
3.1.2 Screening and Treatment Period ................................ ................................ ........ 41
3.2 Duration and Study  Completion Definition ................................ ................................ .42
3.3 Sites and Regions ................................ ................................ ................................ ......... 43
4. STUDY POPUL ATION ........................................................................................................44
4.1 Inclusion Criteria
................................ ................................ ................................ ......... 44
4.2 Exclusion Criteria ................................ ................................ ................................ ........ 44
4.3 Restrictions ................................ ................................ ................................ .................. 46
4.4 Reproductive Potential ................................ ................................ ................................ .46
4.4.1 Female Contraception ................................ ................................ ........................ 46
4.4.2 Male Contraception ................................ ................................ ............................ 47
For non-commercial use only
Shire CONFIDENTIAL Page 9
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
4.5 Discontinuation of Subjects .........................................................................................47
4.5.1 Reasons for Discontinuation ..............................................................................47
4.5.2 Subjects “L ost to Follow -up” Prior to Last Scheduled Visit .............................48
4.5.3 Stopping Criteria for Dose Escalation ...............................................................48
5. PRIOR AND CONCOMITAN T TREATMENT ..................................................................50
5.1 Prior Treatment ............................................................................................................50
5.2 Concomitant Treatment ...............................................................................................50
5.2.1
Permitted Treatment ...........................................................................................50
5.2.2 Prohibited Treatment ..........................................................................................50
6. INVESTIGAT IONAL PROD UCT........................................................................................51
6.1 Identity  of Investigational Product ...............................................................................51
6.1.1 Blinding the Treatment Assignment ..................................................................51
6.2 Administration of I nvestigational Product(s) ...............................................................52
6.2.1 Allocation of Subjects to Treatment ..................................................................52
6.2.2 Dosing ................................................................................................................53
6.2.3 Unblinding the Treatment Assignment ..............................................................53
6.2.4 Labeling .............................................................................................................54
6.2.5 Packaging ...........................................................................................................54
6.2.6 Storage ...............................................................................................................54
6.3 Drug Accountability .....................................................................................................55
6.4
Subject Compliance ................................ ................................ ................................ .....56
6.5 Retention of Bioavailability  and Bioequivalence Testing Samples .............................56
7.
STUDY PROCEDURES .......................................................................................................57
7.1 Study  Schedule .............................................................................................................57
7.1.1 Screening Period ................................................................................................57
7.1.2 Treatment Period ................................................................................................58
7.1.3 Follow -up Period ...............................................................................................59
7.1.4 Additional Care of Subjects after the Stud y
................................ ...................... 59
7.2 Study  Evaluations and Procedures................................ ................................ ............... 59
7.2.1 Demographic and Other Baseline Characteristics ................................ ............. 59
7.2.2 Safety .................................................................................................................59
7.2.3 Pharmacokinetic Procedures ................................ ................................ .............. 65
7.2.4 Pharmacod ynamic Assessm ents................................ ................................ ........ 66
7.2.5 Pharmacogenomic Assessments ................................ ................................ ........ 66
7.2.6 Exploratory  Assessments ................................ ................................ ................... 67
7.2.7 Volume of Blood to be Drawn from Each Subject ................................ ............ 68
8. ADVERSE AND SERIOUS ADVERSE EVENTS ASSES SMENT ...................................69
For non-commercial use only
Shire CONFIDENTIAL Page 10
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
8.1 Definition of Adverse Events, Period of Observation, Recording of Adver se 
Events ...........................................................................................................................69
8.1.1 Severity  Categorization ......................................................................................69
8.1.2 Relationship Categorization ...............................................................................70
8.1.3 Outcome Categorization ....................................................................................70
8.1.4 Clinical L aboratory  and Other Safet y Evaluations ............................................70
8.1.5 Pregnancy ...........................................................................................................71
8.1.6 Abuse, Misuse, Overdose, and Medication Error ..............................................71
8.2 Serious Adverse Event Procedures ..............................................................................72
8.2.1 Reference Safet y Information ............................................................................72
8.2.2 Reporting Procedures .........................................................................................72
8.2.3 Serious Adverse Event Definition .....................................................................73
8.2.4 Serious Adverse Event Collection Time Frame .................................................73
8.2.5 Serious Adverse Event Onset and Resolution Dates .........................................74
8.2.6 Fatal Outcome ....................................................................................................74
8.2.7 Regulatory  Agency , Institutional Review Board, Ethics Committee, and 
Site Reporting
....................................................................................................74
9. DATA MANAGEMENT AND STATISTICAL METHODS ..............................................75
9.1 Data Collection ............................................................................................................75
9.2 Clinical Data Management ..........................................................................................75
9.3
Data Handling Considerations .....................................................................................75
9.4 Statistical Analy
sis Process ..........................................................................................75
9.5 Planned Interim Anal ysis, Adaptive Design, and Data Monitoring Committee ..........76
9.6
Sample Size Calculation and Power Considerations ...................................................77
9.7 Study  Population ..........................................................................................................77
9.8 Pharmacokinetic Analy ses...........................................................................................78
9.8.1 Pharmacokinetic Analy sis..................................................................................78
9.9 Safety  Anal yses............................................................................................................80
9.10 Exploratory  Anal ysis...................................................................................................81
10. SPONSOR’S AND I NVE STIGATOR’S RESPONSIB ILITIES..........................................82
10.1
Sponsor’s Responsibilities...........................................................................................82
10.1.1 Good Clinical Practice Compliance ................................ ................................ ...82
10.1.2 Public Posting of Study  Information ................................ ................................ ..82
10.1.3 Indemnity /Liability  and Insurance ................................ ................................ .....82
10.1.4 Submission of Summary  of Clinical Study  Report to Competent Authorities 
of Member States Concerned and Ethics Committees .......................................82
10.1.5 Study  Suspension, Termination, and Completion
..............................................83
10.2 Investigator’s Responsibilities................................ ................................ ..................... 83
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 12
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
ABBREVIATIONS
ADA anti-drug antibody
AE adverse event
-hCG beta-human chorionic gonadotropin
CRC clinical research center
CRF case report form
CRO contract research organization
DMC data monitoring committee
EC ethics committee 
ECG electrocardiogram 
EU European Union
FDA Food and Drug Administration
FIH first in human
GCP Good Clinical Practice
HIPAA Health Insurance Portability and Accountability Act
ICH International Conference on Harmonisation
IP investigational product
IRB Institutional Review Board
MAD multiple ascending dose
nADA neutralizing anti- drug antibody
PK pharmacokinetic
SAD single ascending dose 
SAE serious adverse event 
SAP statistical anal ysis plan 
SC subcutaneous
SBS short bowel s yndrome
US United States
For non-commercial use only
Shire CONFIDENTIAL Page 13
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
STUDY SYNOPSIS
Protocol num ber: SHP681 -101 Drug: SHP681
Title of the study: A Randomized, Double -blind, Placebo -controlled, Phase 1 Study to Assess the Safety,
Tolerability, and Pharmacokinetics of Ascending, Subcutaneous, Single and Multiple Doses of SHP681 (GLP -2 
analog -Fc fusion) in Healthy Adult Subjects
Number of subjects (total and for each treatm ent arm):
A total of 102 subjects (30 for the single ascending dose [SAD] portion and 72 subjects for the multiple 
ascending dose [MAD] portion) are planned to be enrolled for this study.
Investigator(s): 
Site(s) and Region(s):
Study period (planned):
Feb 2019 -Jan 2020Clinical phase: 1
Objectives:
Prim ary: To assess the safety and tolerability of single and multiple, ascending, subcutaneous (SC) doses of
SHP681 in healthy adult subjects
Secondary: To characterize the pharmacokinetics (PK) of SHP681 following single and multiple, ascending SC 
doses in healthy adult subjects
Rationale:
SHP681 has been engineered with a significant half -life extension compared to teduglutide. This extended 
half-life is expected to allow  once weekly injection with similar safety and efficacy as teduglutide.
The present study is a first in human study to assess the safety, tolerability, and pharmacokinetics of SHP681 
when administered as single and multiple ascending SC doses.
Investigational product, dose, and mode of administration:
Investigational product (IP): SHP681 refers to a glucagon -like peptide -2 (GLP -2) analog -Fc fusion protein, 
abbreviated as GLP -2 analog -Fc fusion. The IP w ill be referred to as SHP681 through this document
SAD portion of the study -Dose escalation with single SC doses of SHP681: 0.2 mg/kg, 0.5 mg/kg, 1 mg/kg, 
2 mg/kg, and 4 mg/kg vs. placebo.
MAD portion of the study -Sequential dose escalation of SC doses of SHP681: 0.2 mg/kg, 0.5 mg/kg, 
1mg/kg, 2 mg/kg, and 4 mg/kg. Each of th e first 5 MAD cohorts will receive SHP681 (or placebo) once 
weekly for 5 w eeks. The 6thMAD cohort w ill receive 4 mg/kg SHP681 once every 2 w eeks for 6 w eeks 
(3doses). 
All subjects (both SAD and MAD portions) will have the IP administered in the abdomen.
Methodology:
SAD -Part 1: The plan is to enroll 30 subjects in 5 cohorts. Each cohort w ill include 6 subjects. Subjects w ill be 
randomized within each cohort such that 5 subjects receive SHP681 and 1 subject receives placebo. Dose 
escalation will proceed sequentially to assess the following SC doses of SHP681: 0.2 mg/kg, 0.5 mg/kg, 1 mg/kg, 
2 mg/kg, and 4 mg/kg. After a single administration of SHP681 or placebo in each cohort, if the dose is assessed 
as safe and tolerable during a dose escalation meeting, the next cohort will be administered a SC dose of SHP681 
at the next higher dose level or placebo. During dose escalation, protocol defined dose levels may be reduced, 
repeated, discontinued, or an intermediate increase may be added depending on the outcome of the blinded safety 
data review  between dose escalations. Upon completion of these 5 -dose cohorts, additional doses may be studied 
based on emergent safety data.
The study duration of the SAD portion of the study will consist of a screening p eriod of up to 28 days and 
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 15
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Exclusion Criteria:
1.History ofanyhematological, hepatic, respiratory, cardiovascular, renal, neurological orpsychiatric
disease, gallbladder removal, orcurrent orrecurrent disease thatcould affect theaction, absorption, or 
disposition oftheinvestigational product, orclinical orlaboratory assessments.
2.Current orrelevant medical history ofphysical orpsychiatric illness, anymedical disorder thatmayrequire 
treatment orrender thesubject unlikely tocomplete thestudy, oranycondition thatpresents undue risk 
from theinvestigational product orprocedures.
3.Known orsuspected intolerance orhypersensitivity totheinvestigational product(s), closel y-related 
compounds, oranyofthestated ingredients.
4.Significant illness, asjudged bytheinvestigator, within2weeks ofthefirstdose ofinvestigational product.
5.Known history ofalcohol orother substance abuse within thelastyear.
6.Donation ofblood orblood products (eg,plasma orplatelets) within 60days prior toreceiving thefirst
dose of investigational product.
7. Within 30daysprior tothefirstdose ofinvestigational product:
a.Have used aninvestigational product (ifelimination half-lifeis<6days, otherwise 5half-lives).
b.Have been enrolled inaclinical study.
c.Have hadanysubstantial changes ineating habits, asassessed bytheinvestigator.
8.UseofDPP-4inhibitors within30daysor5half-lives, whichever isgreater, prior toadministration ofthe 
investigational product.
9.Confirmed systolic blood pressure >139mmHg or<89mmHg, anddiastolic blood pressure >89mmHg or 
<49mmHg.
10. Tw elve - lead ECG demonstrating QTcF >450 msec atscreening. IfQTcF exceeds 450msec, theECG 
should berepeated 2moretimes andtheaverage ofthe3QTcF values should beused todetermine the 
subject’s eligibility.
11. Positive screen foralcohol orillicit drugs atscreening orDay -1.
12. Male subjects who consume more than 21units ofalcohol perweekor3 units perday. Female subjects 
who consume more than 14units ofalcohol perweekor2 units perd
ay.(1alcohol unit=1 beer or1 wine 
(5oz/15 0mL) or1liquor (1.5oz/40 mL) or0.75 ozalcohol).
13. Positive HIV, HBsAg, orHCV antibody screen.
14. Use oftobacco inanyform (eg,smoking orchewing) orother nicotin e -containing products inanyform 
(eg,gum, patch). Ex-users must report thatthey have stopped using tobacco foratleast 30days prior to 
receiving thefirstdose ofinvestigational product.
15. Routine consum ption ofmore than 2units ofcaffeine per day orsubjects who report developing
headaches associated with caffeine withdra wal.(1caffeine unitiscontained inthe following items: one
6 oz (180mL) cupofcoffee, two 1 2 oz (360mL) cans ofcola, one12 oz cupoftea,three 1 oz (85g)
chocolate bars. Decaffeinated coffee, tea,orcola arenot c onsidered tocontain caffeine).
16. Prior screen failure (unless Sponsor approval is given), random ization, participation, orenrollment inthis
study orprior exposure toany GLP
-2analogs.
17. Unresected GI polyp,known polyposis condition, orpremalignant changes intheGItract.
18. Any history ofmalignancy intheGItract ortreatment foranyother malignancy intheprevious 5years.
19. Current useofanymedication (including ove r-the-counter, herbal, orhomeopathic preparations; with the 
exception ofhorm onal replacement therapy orhorm onal contraceptives andoccasional useofibuprofen or 
acetaminophen and pre- approved medication for sedation or other medications required during or after the 
endoscopy ).Current useisdefined asusewithin 14days ofthefirstdose ofinvestigational product.
20. Finding s of subclinical hepatobiliary disease, such as gallstones, on abdominal ultrasound at screening as 
determined by the Investigator in consultation with the Medical Monitor.
For non-commercial use only
Shire CONFIDENTIAL Page 16
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Maximum duration ofsubject involvement inthestudy: 
SAD -Part1
Planned duration ofscreening period: 28days
Planned duration oftreatment period: 29days
Themaximum total duration ofstudy participation fora subject is57days (approximately 2months)
MAD-Part2
Planned duration ofscreening period: 28days
Planned duration oftreatment period: 57days
Themaximum total duration ofstudy participation fora subject is85days (approximately 3months)
Endpoints andstatistical analysis:
Endpoints and Statistical Analysis
Subject populations areseparately defined toanalyze thedata intheSAD portion andtheMAD portion:
SAD
The SAD safety analysis data set includes subjects who have received at least 1 dose of SHP681or placebo in 
the SAD portion.
The SAD PK analysis data set consists of subjects who have received at least 1 dose of SHP681 and have at 
least 1 evaluable post -dose PK concentration value in the SAD portion.
MAD
The MAD safety analysis data set includes subjects who have received at least 1 dose of SHP681or placebo 
in the MAD portion.
TheMAD PKanalysis data setconsists ofsubjects who have received atleast 1dose ofSHP681 and have at
least 1evaluable post-dose PKconcentration value intheMADportion.
Pharmacokinetic Endpoints:
Pharmacokinetic parameters including exposure andproperty param eters willbecalculated for individual
subjects using plasma SHP681 concentratio n-time data andnon-compartmental analysis for both SAD and
MAD parts andallcalculations willbebased onactual sampling times.Effect of ant i-drug antibody (ADA)
andneutralizing anti-drug antibody (nADA) onPKwillbeevaluated. 
ThePKanalysis willbebased onthePKanalysis set.
Pharmacokinetic parameters willbecalculated from plasma SHP681 concentratio n-timedatausing 
non-compartm ental methods andallcalculations willbebased onactual sampling times. Pharm acokinetic 
parameters willinclude, butnot be limited to,thefollowing:
SAD
Cmax: Maximum concentration occurring attmax
tlast: Timeofthelastmeasurable concentration
tmax: Timeofmaximum observed concentration sampled during adosing interval
AUC0-last: Area under thecurve from thetime ofdosing tothelast measurable concentration
AUC0-∞: Area under thecurve extrapolated toinfinity
t1/2
: Terminalhalf-life
z: First order rateconstant associated withtheterminal (log-linear) portion ofthecurve
CL/F: Apparent total body clearance forextravascular administration divided by thefraction ofdose
absorbed calculated asdose divided byAUC 0-∞.
Vz/F: Apparent volume ofdistribution following extravascular administration divided bythefraction
ofdose absorbed calculated asCL/F divided byz.
For non-commercial use only
Shire CONFIDENTIAL Page 17
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
MAD
Post first dose
AUC0-24: Area under thecurve from thetime ofdosing tothe24hours post first dose
Cmax,24 : Maximum concentration occurring during 24hours after firstdose
tmax,24 : Tim
eofmaximum observed concentration during 24hours after first dose
Between thefirst dose and lastdose
Ctrough: Observed concentration attheendofeach dosing interval
(immediately before next dose for the first 5 cohorts and immediately before 2ndand 3rddose of 
the 6thMAD cohort)
Post last dose
Cmax: Maximum concentration during thedosing interval occurring attmax
Tlast: Timeofthelastmeasurable concentration
tmax: Timeofmaximum observed concentration during thedosinginterval
AUCtau:Area under thecurve forthedefined interval betweendoses (only calculated ifinterpretable)
AUC0-last: Area under thecurve from thetime ofdosing tothelast measurable concentration post lastdose
AUC0-∞:Area under thecurve (post lastdose) extrapolated toinfinity, calculated using theobserved value ofthe
lastnon
-zero concentrations (only calculated if interpretable)
t1/2 Terminalhalf-life
z First order rateconstant associated withtheterminal (log-linear) portio n ofthecurve
CL/F Apparent total body clearance following extravascular administration divided bythefraction of
dose absorbed calculated asdose divided byAUC tau
Vz/F Apparent volume ofdistribution following extravascular administration divided bythefraction
ofdose absorbed calculated asCL/F divided byz
Safety Endpoints:
Forboth theSAD andMADportions, thesafety andtolerability ofescalating SCdoses ofSHP681 w illbe
evaluated byexamining foreach cohort: number,severity, seriousness andcausality ofall treatment -emergent
adverse events (TEAEs), including injection siteandhypersensitivity reactions, changes invital signs, ECGs,
abdominal ultrasounds, and clinical laboratory results (hematology, chemistry, and urinalysis) from baseline to
post-baseline timep oints, incidence ofanti-drug antibodies (ADA) toSHP681 andincidence ofneutralizing anti-
drugantibodie s(nADA ) toSHP681.
Sample Size Justification:
SAD
Itisplanned thatdose escalation willproceed forupto5dose levels. Each cohort willinclude 5 subjects treated
withSHP681 and1 subjec ttreate d withplacebo foraplanned total of 30 subjects. However, ifdose levels are
repeated, modified, ornotconducted orifadditional dose levels are studied, thetotal number ofsubjects may
change. Thenumberofsubjects is expected toprovide reasonable information oninitial testing ofSHP681 for
safety andPKwhile exposing asfewsubjects as possible toinvestigational drug materials. Thenumber ofsubjects
inthisstudy isnotbased on statistical hypothesi stestin gandpowerconsiderations asthisisthefirstinhuman
study. Thestatistical analyses areprimarily descriptive, andnohypothesis testing isspecified forthisportion.
MAD
Itisplanned thatthe MAD portion of the study will include 6 cohorts .Each cohort willinclude 1 0 subjects treated
withSHP681 and2 subject streate d withplacebo fora planned total of72 subjects. The number ofsubjects is
expected toprovide reasonable information oninitial testing ofSHP681 forsafety andPKwhile exposing asfew
subjects as possible toinvestigational drug materials. The number of subjects in this study is not based on 
For non-commercial use only
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 20
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
STUDY SCHEDULE(S)
Table 1Schedule of Assessm ents (SAD Portion)
Visit Screening Treatment Period (All Cohorts)
Stud yDay –28to-2 -1 1 2 3 4 5 6 8 11 15 22 29
Informed consent X
Inclusion/exclusion criteria X X
Demographics and medical/medication history X
Physical examination (Including Height and
Weight)a,b X X X X
Vital signs (body temperature, blood
pressure, pulse)a,c X X X X X X X X X X X X X
Electrocardiogram ( 12-lead)a,dX X X X X X X
Biochemistry, hematology, and urinalys isa,j, lX X X X X XmX
HIV, HBsAg, and HCV antibodies X
Pregnancy test (women only)a,eX X X X X X X
Urine drug and alcohol screeningfX X X X X X
Randomization Xi
SHP681 or placebo administration X
Pharmacokinetic blood samplinggX X X X X X X X X X X
ADA and nADA sampling X X
Admit to CRC X
Discharge from CRChX
Outpatient visit XkXkXkXk
Adverse events/serious adverse eventsaX X X X X X X X X X X X X
Concomit ant medicati onaX X X X X X X X X X X X X
For non-commercial use only
Shire CONFIDENTIAL Page 21
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Table 1Schedule of Assessm ents (SAD Portion)
Visit Screening Treatment Period (All Cohorts)
Stud yDay –28to-2 -1 1 2 3 4 5 6 8 11 15 22 29
β-hCG=beta human chorionic gonadotropin; CRC=clinical research center ; HBsAg=hepatitis B surface antigen; HCV=hepatitis C virus; HIV=human immunodeficiency virus
aIn the event a subject prematurely withdraws or is discontinued from the study, every attempt should be made to complete thes e assessments.
bHeight will be recorded at the screening visit only.
c Vital signs will be obtained while the subject is seated for 5 minutes on study days noted. Oral temperature should be taken by placing a digital thermometer under the tongue for 
at least 30 seconds and the temperature reported in degrees Celsius. Tympanic temperature may also be used. Whichever procedu re is used should be the same procedure 
throughout the study.
d 12-lead electrocardiograms will be performed at each timepoint; these assessments should be performed within 15 minutes of the p lanned timepoint. The subject should not have 
exercised or consumed caffei ne, alcohol, or nicotine within 30 minutes prior to collection. The subject must be resting in the supine position for at lea st 5 minutes prior to 
collecting the ECG.
eSerum β -hCG test at screening is required for all women. Urine pregnancy test is requir ed for all women at subsequent scheduled timepoints
fDrugs of abuse at screening and drugs of abuse and alcohol on Day -1, Day 11, Day 15, Day 22, and Day 29; a breathalyzer test for alcohol may be done if more convenient than 
a urine alcohol test.
gSeeTable 2 for detailed collection timepoints.
h Subject to be discharged following the completion of all assessments on Day 8.
iRandomization to SHP681 or placebo will occur on Day -1 or Day 1 only.
j Urine collections should be from the first void of the d ay while the subjects are confined to the unit; during outpatient visits, urine may be obtained at any time during the visit.
k A window of +/ - 1 day is allowed for outpatient visits on Days 11, 15, 22, and 29 to allow for subject flexibility.
l Full thyro id panel (T3, T4, TSH, Free T3 and Thyroxine -binding globulin [TBG]) on Day 1 (Predose), Day 8 and Day 15.
m On Day 15, only a full thyroid panel (T3, T4, TSH, Free T3, and Thyroxine -binding globulin [TBG]) will be collected.
For non-commercial use only
Shire CONFIDENTIAL Page 22
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Table 2 Detailed Schedule of Assessments for SAD
Stud yDay Day 1Day
2Day
3Day
4Day
5Day
6Day
8Day
11Day
15Day
22Day
29
Hour (relative to dosing time)Pre 
dose0 3 6 12 24 48 72 96 120 168 240 336 504 672
Physical examination (Including Height and Weight)a,bX X
Vital signs (body temperature , blood pressure, pulse)a, cXeX X X X X X X X X X X X X
Electrocardiogram ( 12-lead)a,dXeX X X X X X X
Biochemistry, hematology, and urinalysisa,f, gXeX X XhX
SHP681 or placebo administration X
Pharmacokinetic blood sampling XeX X X X X X X X X X X X X
ADA and nADA blood sampling XeX
Adverse events/serious adverse eventsaX X X X X X X X X X X X X X X
Concomitant medicati onaX X X X X X X X X X X X X X X
aIn the event a subject is prematurely discontinued from the study or withdraws, every attempt should be made to complete thes e assessments.
bHeight will be recorded at the screening visit only.
cVital signs will be obtained while the subject is seated for 5 minutes on study days noted. Oral temperature should be taken by placing a digital thermometer under the tongue for 
at least 30 seconds and the temperature reported in degrees Celsius. Tympani c temperature may also be used. Whichever procedure is used should be the same procedure 
throughout the study.
d12-lead electrocardiograms will be performed at each timepoint; the subject should not have exercised or consumed caffeine, alco hol, or nicotin e within 30 minutes prior to 
collection. The subject must be resting in the supine position for at least 5 minutes prior to collecting the ECG.
eThese assessments should be performed within 30 minutes prior to dose administration.
fUrine collections shou ld be from the first void of the day while the subjects are confined to the unit; during outpatient visits, urine may be obta ined at any time during the visit.
gFull thyroid panel (T3, T4, TSH, Free T3 and Thyroxine-binding globulin [TBG]) on Day 1 (Predo se), Day 8 and Day 15.
hOn Day 15, only a full thyroid panel (T3, T4, TSH, Free T3, and Thyroxine -binding globulin [TBG]) will be collected.
For non-commercial use only
Shire CONFIDENTIAL Page 23
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Table 3 Schedule of Assessments (MAD Portion for Cohorts 1-5)- Part 1
Visit Screening Treatment Period (Cohorts 1 -5)
Stud yDay –28to-2 -1 1 2 3 4 7 8 10 14 15 18 21 22 24
Informed consent X
Inclusion/exclusion criteria X X
Dem ographics and medical/medication history X
Physical examination (Including Height and Weight) 
a,bX X X XkXkXk
Vital signs (body temperature, blood pressure, 
pulse)a,cX X X X X X X X X X X X
Electrocardiogram ( 12-lead)a,dX X X X X X X X X
Biochemistry, hematology, and urinalys isa,lX X X X X X X X
HIV, HBsAg, and HCV antibodies X
Pregnancy test (women only)a,eX X X X X X X X X
Urine drug and alcohol screeni ngf X X X X X
Randomization Xj
SHP681 or placebo administration X X X X
Pharmacokinetic blood samplinggX X X X X
ADAand nADA blood sampling X X X X
 X
Admit to CRC X X X X
Discharge from CRCiX X X X
Outpatient visit
Upper GI endoscopy with biopsy X
Adverse events/serious adverse eventsaX X X X X X X X X X X X X X X
Concomitant medicati onaX X X X X X X X X X X X X X X
βhCG=beta human chorionic gonadotropin; CRC=clinical research center ; HBsAg=hepatitis B surface antigen; HCV=hepatitis C virus; HIV=human immunodeficiency virus
aIn the event a subject prematurely withdraws or is discontinued from the study, every attempt should be made to complete thes e assessmen ts.
bHeight will be recorded at the screening visit only.
cVital signs will be obtained while the subject is seated for 5 minutes on study days noted. Oral temperature should be taken by placing a digital thermometer under the tongue for 
at least 30 seco nds and the temperature reported in degrees Celsius. Tympanic temperature may also be used. Whichever procedure is used shoul d be the same procedure 
throughout the study.
d12-lead electrocardiograms will be performed at each timepoint; these assessments s hould be performed within 15 minutes of the planned timepoint. The subject should not have 
exercised or consumed caffeine, alcohol, or nicotine within 30 minutes prior to collection. The subject must be resting in th e supine position for at least 5 minutes prior to 
collecting the ECG.
eSerum β -hCG test at screening is required for all women. Urine pregnancy test is required for all women at subsequent scheduled timep oints
fDrugs of abuse at screening and drugs of abuse and alcohol on Day -1, Day 7, Day 14 , Day 21, Day 28; Day 39, Day 43, Day 50, Day 57 a breathalyzer test may be done if more 
convenient than a urine alcohol test.
gSee Table 4 and Table 5 for detailed collection timepoints. 
hSubjects must fast for at least 8 hours prior to collection
i Subject to be discharged following the last assessment on study days noted. The inhouse period may be revised due to operationa l issues pending approval by the PI and Sponsor.
For non-commercial use only
Shire CONFIDENTIAL Page 24
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Table 3 Schedule of Assessments (MAD Portion for Cohorts 1-5)- Part 1
Visit Screening Treatment Period (Cohorts 1 -5)
Stud yDay –28to-2 -1 1 2 3 4 7 8 10 14 15 18 21 22 24
jRandomization to SHP681 or placebo will occur on Day -1 or Day 1 only.
kAbbrevi ated physical exam will be performed (includes minimally general appearance; head, eyes, ears, nose, and throat; cardiovascul ar; respiratory; neurological; abdomen; and 
skin) on study days noted.
lUrine collections should be from the first void of the day while the subjects are confined to the unit; during outpatient vis its, urine may be obtained at any time during the visit.
For non-commercial use only
Shire CONFIDENTIAL Page 25
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Table 3 Schedule of Assessments (MAD Portion for Cohorts 1-5)- Part 2
Visit Treatment Period (Cohorts 1 -5)
Stud yDay28 29 30 31 32 33 34 36 39 43 50 57
Informed consent
Inclusion/exclusion criteria X
Demographics and medical/medication history
Physical examination (Including Height and Weight) a,bXjX XjX
Vital signs (body temperature, blood pressure, pulse)a,cX X X X X X X X X X X X
Electrocardiogram ( 12-lead)a,dX X X X X X
Biochemistry, hematology, and urinalys isa,lX X X X X
HIV, HBsAg, and HCV antibodies
Pregnancy test (women only)a,eX X X X X X
Urine drug and alcohol screeni ngfX X X X X
Randomization
SHP681 orplacebo administration X
Pharmacokinetic blood sampli nggX X X X X X X X X X X
ADA and nADA blood sampling X X X
 X X
Admit to CRC X
Discharge from CRCiX
Outpatient visit XmXmXmXm
Upper GI endoscopy with biopsy Xk
Adverse events/serious adverse eventsaX X X X X X X X X X X X
Concomitant medicati onaX X X X X X X X X X X X
For non-commercial use only
Shire CONFIDENTIAL Page 26
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Table 3 Schedule of Assessments (MAD Portion for Cohorts 1-5)- Part 2
Visit Treatment Period (Cohorts 1 -5)
Stud yDay28 29 30 31 32 33 34 36 39 43 50 57
βhCG=beta human chorionic gonadotropin; CRC=clinical research center ; HBsAg=hepatitis B surface antigen; HCV=hepatitis C virus; HIV=human immunodeficiency virus
aIn the event a subject prematurely withdraws or is discontinued from the study, every attempt should be made to complete thes e assessments.
bHeight will be recorded at the screening visit only.
cVital signs will be obta ined while the subject is seated for 5 minutes on study days noted. Oral temperature should be taken by placing a digital the rmometer under the tongue for at 
least 30 seconds and the temperature reported in degrees Celsius. Tympanic temperature may also be used. Whichever procedure is used should be the same procedure throughout the 
study.
d12-lead electrocardiograms will be performed at each timepoint; these assessments should be performed within 15 minutes of the p lanned timepoint. The subject should not have 
exercised or consumed caffeine, alcohol, or nicotine within 30 minutes prior to collection. The subject must be resting in th e supine position for at least 5 minutes prior to collecting 
the ECG.
eSerum β -hCG test at screening is required for all wom en. Urine pregnancy test is required for all women at subsequent scheduled timepoints.
fDrugs of abuse at screening and drugs of abuse and alcohol on Day -1, Day 7, Day 14, Day 21, Day 28; Day 39, Day 43, Day 50, Day 57 a breathalyzer test may be done if more 
convenient than a urine alcohol test.
gSeeTable 6for detailed collection timepoints. PK timepoints post day 33 can have a -/+ one day window.
hSubjects must fast for at least 8 hours prior to collection
iSubject to be discharged following the last assessment on study days noted. The inhouse period may be revised due to operatio nal issues pending approval by the PI and Sponsor.
jAbbreviated physical exam will be performed (includes minimally general appea rance; head, eyes, ears, nose, and throat; cardiovascular; respiratory; neurological; abdomen; and 
skin) on study days noted
k This procedure will be performed on Day 36 (ie, window of +/-3 days).
lUrine collections should be from the first void of the da y while the subjects are confined to the unit; during outpatient visits, urine may be obtained at any time during the visit.
mA window of +/ - 1 day is allowed for outpatient visits on Days 39, 43, 50, and 57 to allow for subject flexibility.
For non-commercial use only
Shire CONFIDENTIAL Page 27
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Table 4 Detailed Schedule of Assessments for MAD Cohorts 1- 5 (Day 1 to Day 4)
Study Day Day 1 Day 2 Day 3 Day 4
Hour(relativ e todosing time)Pre 
dose0 3 6 12 24 48 72
Physical examinatio n(Including Heigh tandWeight )a, bXg
Vital signs (bod ytemperatur e, bloodpressure, pulse)a, cXfX X X X X X
Electrocardiogram (12-lead)a,dXfX X X X X X
Biochemistry, he matology, andurinalysisa,hXfX X
SHP68 1 orplacebo administration X
Pharmacokinetic b loodsampling XfX X X X
ADA andnADAbloodsampling Xf
Xf
Uppe rGIendoscopy with biopsy
Adverse events/serious adv erseevent saX X X X X X X X
Concomitant medicati onaX X X X X X X X
aIn the event a subject is prematurely discontinued from the study or withdraws, every attempt should be made to complete thes e assessments.
bHeight will be recorded at the screening visit only.
c Vital signs will be obtained while the subject is seated for 5 minutes on study days noted. Oral temperature should be taken by placing a digital thermometer under the tongue for 
at least 30 seconds and the temperature reported in degrees Celsius. Tympanic temperature may also be used. Whichever procedu re is used should be the same procedure 
throughout the study.
d12-lead electrocardiograms will be performed at each timepoint; the subject should not have exercised or consumed caffeine, alco hol, or nicotine within 30 minutes prior to 
collection. The subject must b e resting in the supine position for at least 5 minutes prior to collecting the ECG.
e Subjects must fast for at least 8 hours prior to collection.
fThese assessments should be performed within 30 minutes prior to dose administration.
gAbbreviated physic al exam will be performed (includes minimally general appearance; head, eyes, ears, nose, and throat; cardiovascular; respira tory; neurological; abdomen; and 
skin) on study days noted.
h Urine collections should be from the first void of the day while the subjects are confined to the unit; during outpatient visits, urine may be obtained at any time during the visit.
For non-commercial use only
Shire CONFIDENTIAL Page 28
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Table 5 Detailed Schedule of Assessments for MAD Cohorts 1- 5 (Day 7 to Day 22)
Study Day Day 7 Day 8 Day 14 Day 15 Day 21 Day 22
Hour(relativ e todosing time) 0 Predose 0 0 Predose 0 0 Predose 0
Physical examinatio n(Including Heigh tandWeight )a, bXgXgXg
Vital signs (bod ytemperatur e, bloodpressure, pulse)a, cX XfX XgX Xg
Electrocardiogram ( 12-lead)a,dXfXgXg
Biochemistry, h ematology, andurinalysi sa,hXfX X
SHP68 1 orplacebo administration X X X
Pharmacokinetic b loodsampling XfXgXg
ADA andnADAbloodsampling XfXgXg
Uppe rGIendoscopy with biopsy
Adverse events/serious advers eevent saX X X X X X X X X
Concomitant medicati onaX X X X X X X X X
a In the event a subject is prematurely discontinued from the study or withdraws, every attempt should be made to complete th ese assessments.
b Height will be recorded at the screening visit only.
c Vitalsigns will be obtained while the subject is seated for 5minutes onstudydays noted .Oral temperature should be taken by placing a digital thermometer unde rthe tongu e for 
at least 30 seconds and the temperature reported in degrees Celsius. Tympanic temperature may also be used. Whiche ver procedure is used should be the same procedure 
throughout the study.
d 12-lead electrocardiograms will be performed a
teachtimepoint; the subject should nothave exercised orconsumed caffeine, alcohol, ornicotine within 30minute spriorto 
collection. The subject must be resting in the supine position for at least 5 minutes prior to collecting the ECG.
e Subjects must fast f or at least 8 hours prior to collecti on.
f These assessments should be performed within 30 minutes prior to dose administration.
g Abbreviated physical exam will be performed (includes minimally general appearance; head, eyes, ears, nose, and throat; card iovascular; respiratory; neurological; abdomen; and 
skin) on study days noted.
h Urine collections should be from the first void of the day while the subjects are confined to the unit; during outpatient vi sits, urine may be obtained at any time during the v isit.
For non-commercial use only
Shire CONFIDENTIAL Page 29
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Table 6         D etailed Schedule of Assessments for MAD Cohorts 1 -5 (Day 28 to Day 57)
Study DayDay
28D
ay29Day
30Day
31Day
32Day
33Day
34Day
36Day
39Day
43Day
50Day
57
Hour(relativ e todosing time) 0 Predose 0 3 6 12 24 48 72 96 120 168 240 336 504 672
Physical examinatio n(Including 
Height andWeight )a, b XgXgXgX
Vital signs (bodytemperatur e, 
bloodpressure, pulse )a, c X XfX X X X X X X X X X X X X
Electrocardiogram ( 12-lead)a,dX XfX X X X X X X
Biochemistry, h ematology, and 
urinalysi sa,i X XfX X X
SHP68 1 orplacebo
administrationX
Pharmacokinetic blood sampling XfX X X X X X X X X X X X X
ADA andnADAbloodsampling XfX X
X X
Uppe rGIendoscopy with biopsy Xh
Adverse events/serious adve rse 
event sa X X X X X X X X X X X X X X X X
Concomitant medicati onaX X X X X X X X X X X X X X X X
a In the event a subject is prematurely discontinued from the study or withdraws, every attempt should be made to complete these assessments.
bHeight will be recorded at the screening visit only.
cVital signs will be obtained while the subject is seated for 5 minutes on study da ys noted. Oral temperature should be taken by placing a digital thermometer under the tongue for 
at least 30 seconds and the temperature reported in degrees Celsius. Tympanic temperature may also be used. Whichever procedu re is used should be the same proc edure 
throughout the study.
d12-lead electrocardiograms will be performed at each timepoint; the subject should not have exercised or consumed caffeine, alco hol, or nicotine within 30 minutes prior to 
collection. The subject must be resting in the supine position for at least 5 minutes prior to collecting the ECG.
eSubjects must fast for at least 8 hours prior to collection.
fThese assessments should be performed within 30 minutes prior to dose administration.
gAbbreviated physical exam will be performe d (includes minimally general appearance; head, eyes, ears, nose, and throat; cardiovascular; respiratory; neurological; abdo men; and 
skin) on study days noted.
hThis procedure will be performed on Day 36 (ie, window of +/- 3 days).
iUrine collections sh ould be from the first void of the day while the subjects are confined to the unit; during outpatient visits, urine may be ob tained at any time during the visit.
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 31
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Table 7 Schedule of Assessments for 6th MAD Cohort (Day 1 to Day 57)
Visit Screening Treatment Period (Cohort 6)
Stud yDay -28 -1 1 2 3 4 8 14 15 18 22n28 29 30 31 32 33 34 36 39 43 50o57p
Discharge from 
CRCiX X X
Outpatient visit X X X X X X
Upper GI 
endoscopy with 
biopsyX Xl
Abdominal 
ultrasounda X Xl
Adverse 
events/serious 
adverse eventsaX X X X X X X X X X X X X X X X X X X X X X X
Concomitant 
medicati onaX X X X X X X X X X X X X X X X X X X X X X X
βhCG=beta human chorionic gonadotropin; CRC=clinical research center ; HBsAg=hepatitis B surface antigen; HCV=hepatitis C virus; HIV=human immunodeficiency virus
aIn the event a subject prematurely withdraws or is discontinued from the study, every attempt should be made to complete thes e assessments.
bHeight will be recorded at the screening visit only.
cVital signs will be obtained while the subject is seated for 5 minutes on study days noted. Oral temperature should be taken by placing a digital thermometer under the tongue for at 
least 30 seconds and the temperature reported in degrees Celsius. Tympanic temperature may also be used. Whichever procedure is used should be the same procedure throughout the 
study.
d12-lead electrocardiograms will be performed at each timepoint; these assessments should be performed within 15 minutes of the p lanned timepoint. The subject should not have 
exercised or consumed caffei ne, alcohol, or nicotine within 30 minutes prior to collection. The subject must be resting in the supine position for at lea st 5 minutes prior to collecting the 
ECG.
eSerum β -hCG test at screening is required for all women. Urine pregnancy test is requir ed for all women at subsequent scheduled timepoints
fDrugs of abuse at screening and drugs of abuse and alcohol on the remainder of study days as indicated. A breathalyzer test m ay be done if more convenient than a urine alcohol test.
gSee Table 8 , Table 9, and Table 10 for detailed collection timepoints. PK samples drawn beyond D ay 2 can notdeviate by more than ±10% of the specified time from the first dose.
hSubjects must fast for at least 8 hours prior to collection
iSubject to be discharged following the last assessment on study days noted. The inhouse period may be revised due to operatio nal issues pending approval by the PI and Sponsor.
jRandomization to SHP681 or placebo will occur on Day -1 or Day 1 only.
kAbbr eviated physical exam will be performed (includes minimally general appearance; head, eyes, ears, nose, and throat; cardiovas cular; respiratory; neurological; abdomen; and skin) 
on study days noted.
lThis procedure will be performed on Day 36 (window of + /-3 days).
mUrine collections should be from the first void of the day while the subjects are confined to the unit; during outpatient vis its, urine may be obtained at any time during the visit.
nA window of + / - 2 days is allowed for Day 22 visit to all ow for subject flexibility.
oA window of +/ - 3days is allowed for Day 50 visit to allow for subject flexibility.
pA window of +/ - 4days is allowed for Day 57 visit to allow for subject flexibility.
For non-commercial use only
Shire CONFIDENTIAL Page 32
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Table 8 Detailed Schedule of Assessments for MAD Cohort 6 (Day 1 to Day 4)
Study Day Day 1 Day 2 Day 3 Day 4
Hour(relativ e todosing time)Pre 
dose0 3 6 12 24 48 72
Physical examinatio n(Including Heigh tandWeight )a, bXg
Vital signs (bod ytemperatur e, bloodpressure, pulse)a, cXfX X X X X X
Electrocardiogram (12-lead)a,dXfX X X X X X
Biochemistry, he matology, andurinalysisa,hXfX X
SHP68 1 orplacebo administration X
Pharmacokinetic b loodsampling XfX X X X
ADA andnADAbloodsampling Xf
Xf
Uppe rGIendoscopy with biopsy
Adverse events/serious adv erseevent saX X X X X X X X
Concomitant medicati onaX X X X X X X X
aIn the event a subject is prematurely discontinued from the study or withdraws, every attempt should be made to complete thes e assessments.
bHeight will be recorded at the screening visit only.
c Vital signs will be obtained while the subject is seated for 5 minutes on study days noted. Oral temperature should be taken by placing a digital thermometer under the tongue for 
at least 30 seconds and the temperature reported in degrees Celsius. Tympanic temperature may also be used. Whichever procedu re is used should be the same procedure 
throughout the study.
d12-lead electrocardiograms will be performed at each timepoint; the subject should not have exercised or consumed caffeine, alco hol, or nicotine within 30 minutes prior to 
collection. The subject must b e resting in the supine position for at least 5 minutes prior to collecting the ECG.
e Subjects must fast for at least 8 hours prior to collection.
fThese assessments should be performed within 30 minutes prior to dose administration.
gAbbreviated physic al exam will be performed (includes minimally general appearance; head, eyes, ears, nose, and throat; cardiovascular; respira tory; neurological; abdomen; and 
skin) on study days noted.
h Urine collections should be from the first void of the day while the subjects are confined to the unit; during outpatient visits, urine may be obtained at any time during the visit.
For non-commercial use only
Shire CONFIDENTIAL Page 33
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Table 9 Detailed Schedule of Assessments for MAD Cohort 6 (Day 8 to Day 22)
Study Day Day 8 Day 14 Day 15 Day 22i
Hour(relativ e todosing time) 0 0 Predose 0 0
Physical examinatio n(Including Heigh tandWeight )a, bXgXgXg
Vital signs (bod ytemperatur e, bloodpressure, pulse)a, c X X Xf X
Electrocardiogram ( 12-lead)a,dX XfX
Biochemistry, h ematology, andurinalysi sa,hX XfX
SHP68 1 orplacebo administration X
Pharmacokinetic b loodsamplingjXf
ADA andnADAbloodsampling X XfX
Uppe rGIendoscopy with biopsy
Adverse events/serious advers eevent saX X X X X
Concomitant medicati onaX X X X X
a In the event a subject is prematurely discontinued from the study or withdraws, every attempt should be made to complete th ese assessments.
b Height will be recorded at the screening visit only.
c Vitalsigns will be obtained while the subject is seated for 5minutes onstudydays noted .Oral temperature should be taken by placing a digital thermometer unde rthe tongu e for 
at least 30 seconds and the temperature reported in degrees Celsius. Tympanic temperature may also be used. Whiche ver procedure is used should be the same procedure 
throughout the study.
d 12-lead electrocardiograms will be performed a
teachtimepoint; the subject should nothave exercised orconsumed caffeine, alcohol, ornicotine within 30minute spriorto 
collection. The subject must be resting in the supine position for at least 5 minutes prior to collecting the ECG.
e Subjects must fast for at least 8 hours prior to collecti on.
f These assessments should be performed within 30 minutes pri or to dose administration.
g Abbreviated physical exam will be performed (includes minimally general appearance; head, eyes, ears, nose, and throat; card iovascular; respiratory; neurological; abdomen; and 
skin) on study days noted.
h Urine collections shou ld be from the first void of the day while the subjects are confined to the unit; during outpatient vis its, urine may be obtained at any time during the visit.
iA window of + / - 2days is allowed for Day 22 visit to allow for subject flexibility.
jPK samples drawn beyond Day 2 can notdeviate by more than ±10% of the specified time from the first dose.
For non-commercial use only
Shire CONFIDENTIAL Page 34
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Table 10 Detailed Schedule of Assessments for MAD Cohort 6 (Day 28 to Day 57)
Study DayDay
28 Day 29Day
30Day
31Day
32Day
33Day 
34Day 
36Day
39Day
43Day
50jDay
57k
Hour(relativ e todosing time)0 Predose 0 3 6 12 24 48 72 96 120 168 240 336 504 672
Physical examinatio n(Including 
Height andWeight )a, b XgXgXgX
Vital signs (bodytemperatur e, 
bloodpressure, pulse )a, c X XfX X X X X X X X X X X X X
Electrocardiogram ( 12-lead)a,dX XfX X X X X X X
Biochemistry, h ematology, and 
urinalysi sa,i X XfX X X
SHP68 1 orplacebo
administrationX
Pharmacokinetic blood samplinglXfX X X X X X X X X X X X X
ADA andnADAbloodsampling XfX X
X X
Uppe rGIendoscopy with biopsy Xh
Abdominal ultrasoundaXh
Adverse events/serious adve rse 
event sa X X X X X X X X X X X X X X X X
Concomitant medicati onaX X X X X X X X X X X X X X X X
a In the event a subject is prematurely discontinued from the study or withdraws, every attempt should be made to complete these assessments.
bHeight will be recorded at the screening visit only.
cVital signs will be obtained while the subject is seated for 5 minutes on study days noted. Oral temperature should be taken by placing a digital thermometer under the tongue for 
at least 30 seconds a nd the temperature reported in degrees Celsius. Tympanic temperature may also be used. Whichever procedure is used should be the same procedure 
throughout the study.
d12-lead electrocardiograms will be performed at each timepoint; the subject should not have exercised or consumed caffeine, alco hol, or nicotine within 30 minutes prior to 
collection. The subject must be resting in the supine position for at least 5 minut es prior to collecting the ECG.
eSubjects must fast for at least 8 hours prior to collection.
fThese assessments should be performed within 30 minutes prior to dose administration.
gAbbreviated physical exam will be performed (includes minimally general appearance; head, eyes, ears, nose, and throat; cardi ovascular; respiratory; neurological; abdomen; and 
skin) on study days noted.
hThis procedure will be performed on Day 36 (window of +/ -3 days).
iUrine collections should be from the first void of the day while the subjects are confined to the unit; during outpatient vis its, urine may be obtained at any time during the visit.
jA window of +/ - 3 days is allowed for Day 50 visit to allow for subject flexibility.
kA window of +/ -4 days is allowed for Day 57 visit to allow for subject flexibility.
lPK samples drawn beyond Day 2 can notdeviate by more than ±10% of the specified time from the first dose.
For non-commercial use only
Shire CONFIDENTIAL Page 35
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Table 11 Early Discontinuation Assessments
Study ProcedureEarly Discontinuation Visita,b
Concomitant medications X
Physical examination (including weight)cX
Vital signs (blood pressure, pulse)dX
Biochemistry, hematology, and urinalysis X
Pregnancy testingeX
Abdominal ultrasound X
ADA and nADA blood sampling X
Adverse events/serious adverse eventsfX
aRules for data collection when subjects are discontinued from the study are provided in Section 4.5of the protocol.
b The early discontinuation visit will be conducted at 28 (±7) days after the last dose of investigational product
c Abbreviated physical exam on all subjects (includes minimally general appearance; head, eyes, ears, nose, and throat; 
cardiovascular; respira tory; neurological; abdomen; and skin).
d Vital signs will be measured with the subject in a seated position using standard methods/equipment at the CPU. Subjects 
should be in a seated position for at least 5 minutes prior to the procedure. Vital signs sho uld be measured before the collection of 
blood (eg, safety labs).
eA urine pregnancy test will be performed for all female subjects.
fAll AEs are collected from the time the informed consent is signed through 7 days after the last dose of investigational product. 
Investigators will report all SAEs that occur ≤30 days after the last dose of investigational product and related SAEs that o ccur 
>30 days after the last dose of investigational product to Shire Global Safety Department.
For non-commercial use only
Shire CONFIDENTIAL Page 36
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
1.BACKGROUND INFORMATI ON
1.1 Indication and Current Treatment Options
SHP681 is the Glucago n-like peptid e-2 (GLP-2) analo g-Fc fusion protein, abbreviated as 
GLP-2analog-Fc fusion. The IP will be called SHP681 through this document.
SHP681, a long acting glucagon like pepti de-2 (GL P- 2) analog, is being de veloped for treating 
patients with short bowel syndrome (SBS).
Short bowel sy ndrome is a rare, serious, disabling, socially incapacitating, and potentially
life-threatening condition (Nightingale and Woodward, 2006 ) resulting from surgical resection 
or congenital loss of most of the absorptive surfa ce area of the small intestine (O' Keefe et al., 
2006). Short bowel sy ndrome is characterized by theinabilit yto maintain protein -energy,fluid, 
electro lyte, or micronutrient balances when on a conventionally accepted, normal diet ( O' Keefe 
et al., 2006 ). Causes of SBS in adults include Crohn's disease, mesenteric ischemia, volvulus, 
trauma, surgical complic ations, and cancer.
The prevalence of adults with intestinal failure due to SBS is estimated at 2 -4 million, (Bakker et 
al., 1999 ; Kelly  et al., 2014 ; Mughal and Irving, 1986) while the incidence of neonatal SBS is 
estimated at 24.5 per 100,000 live births ( Wales et al., 2004 ). It is estimated that 83% of pediatric 
cases of SBS begin du ring infancy (Guarino and De Marco, 2003).
Patients with SBS are highly prone to malnutrition, diarrhea, de hydration, electro lyte 
disturbances, malabsorption of nutrients, gastric hypersecretion, metabolic acidosis, 
cholelithiasis, nephrolithiasis, steatorrhea, small bowel bacterial overgrowth and an inability to 
maintain weight due to the reduced intestinal capacity to absorb macronutrients, water, and 
electro lytes (Dudrick et al., 1991 ; Nightingale, 1999 ; Rombeau and Rolandelli, 1987 ; 
Shanbhogue and Molenaar, 1994; Vanderhoof and L angnas, 1997; Wilmore et al., 1997 ;
Nightingale and Woodward, 2006 ; O' Keefe et al., 2006). Complications common to SBS 
include d- lactic acidosis, h yperoxaluria, intestinal failure associated liver disease, and 
anastomotic ulcers.
Short bowel sy ndrome is the leading cause of intestinal failure, defined as the requirement for 
parenteral support (intravenous nutrition and/or flui ds) to maintain health and/or growth (Pironi 
et al., 2016 ). Although parenteral support (PS) is considered li f
e-saving, it is also well associated 
with serious complications s uch as cathet er-associated bloodstream infections, catheter breaka ge, 
central venous thrombosis, metabolic bone disease, and liver disease. The risks of these 
complications increase commensurat ely with the duration of intestinal failure, and as a result, 
patients with intestinal failure have higher mortality rates than those with intestinal insufficiency
(Amiot et al., 2013; Goulet et al., 2005 ).
Some patients with SBS are able to adapt metabolically  and compensate for their malabsorption 
of fluids, electroly tes, trace elements, vitamins, or nutrients by  increasing oral/enteral intake 
(Messing et al., 1999 ; Jeppesen and Mortensen, 2000 ) such that they  can attain enteral 
autonomy  (independence from parenteral support) even though they  continue to have sy mptoms 
of malabsorption (intestinal insuffi ciency ).
For non-commercial use only
Shire CONFIDENTIAL Page 37
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
However, there are limits to the adaptive capacity of the small intestine, especially  in cases 
where the distal ileum and colon have been removed. Such patients often have a compromised 
adaptive response due in part to deficiency  in glucagon -like peptide 2 (GLP- 2), a hormone 
produced by  L-type enteroendocrine cells that reside in these segments of bowel.
In response to the presence of unabsorbed nutrients in the distal ileum and colon, L -type 
enteroendocrine cells release GLP -2, which acts on recep tors in sub -epithelial myofibrobasts 
and enteric neurons. This triggers the release of growth factors that stimulate intestinal 
epithelial stem cell proliferation and inhibit epithelial apoptosis, resulting in increases in villus 
height and cry pt depth, th ereby  increasing the absorptive surface area of the remaining gut. 
Other downstream effects include increases in splanchnic blood flow, inhibition of gastric acid 
production, and slowing of gastric empty ing.
1.2 Product Background
Teduglutide is a recombinant human GLP -2 analog with an Ala2Gly  substitution, which 
increases the half -life from 7 minutes to approximately  2 hours in healthy  subjects and 
1.3hours in adult SBS subjects.
SHP681 is a fusion protein containing 2 moieties of teduglutide, a poly peptide l inker, and 
human IgG1Fc. Based on animal models, the predicted half -life in humans for SHP681 is 
approximately  4 day s, which may  allow once weekly  dosing.
1.2.1 Preclinical Information
SHP681 demonstrated in animal models a longer half -life than teduglutide. The present study  is 
a first in human (FIH) study  to assess the safety , tolerability , and pharmacokinetics of SHP681 
when administered as single and multiple, ascending subcutaneous (SC) doses.
Refer to the Investigator’s Brochure provided under separate cove r for more information.
1.2.2 Clinical Information
Teduglutide has been shown in clinical trials to reduce parenteral support requirements in 
patients with SBS. It is approved in the US (as Gattex®) for the treatment of adults with SBS 
who are dependent on paren teral support, and in Europe (as Revestive®) for treatment of 
patients aged 1 y ear and above with SBS who are stable following a period of intestinal 
adaptation after surgery . Teduglutide is administered at 0.05 mg/kg subcutaneous once daily .
Alway s refer to the latest version of the SHP681 investigator’s brochure for the overall 
risk/benefit assessment and the most accurate and current information regarding the drug 
metabolism, pharmacokinetics, efficacy , and safety  of SHP681.
1.3 Risk/Benefit and Ethical Asse ssment
There is no anticipated benefit from taking part in this stu dy.
Risks for subject exposure to SHP681 are listed in the current investigator brochure.
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 39
SHP681 -101 Protocol Amendment 4
GLP -2 analog -Fc fusion 19 Nov 2019
3.STUDY DESIGN
3.1 Study Design and Flow Chart
This studyisarandomized, doub le-blind, place bo-controlled, Phase 1study toassess thesafety 
andtolerabili ty,andpharmacokinetics ofSHP681 following single andmultiple, ascending, SC 
doses inhealthy adult subjects. This studywillbeconducted atasingle center and5dose levels 
areplanned forboth thesingle-ascending dose (SAD) andmultip le-ascending dose (MAD) parts 
ofthis stu dy. A total of102subjects (30 for theSAD portion and72subjects fortheMAD 
portion) areplanned tobeenrolled forthis stu dy.
Theplan is to enroll intheSAD portion of thestudy 30subjects in5cohorts. Each cohort will 
include 6subjects. Subjects willberandomized within each cohort such that5subjects receive 
SHP681 and1 subject receives placebo.
TheMAD portion of thisstudy may initiate upon completion ofapharmacokinetic andsafety  
data review ofSAD Cohort 1, SAD Cohort 2, andpartial data from SAD Cohort 3(seePart1). 
Theplan is to enroll 72subjects within 6MAD cohorts. Each cohort willinclude 12subjects. 
Subjects willberandomized within each cohort such that10subjects receive SHP681 and 
2subjects receive placebo.
Thestudy design isshown inthestudy schema inFigure 1and Figure 2.
Figure 1Study Design Flow Chart for the SAD portion
For non-commercial use only
Shire CONFIDENTIAL Page 40
SHP681 -101 Protocol Amendment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Figure 2Study Design Flow Chart for the MAD portion
3.1.1 Dose selection, rationale andadministration
SAD (Part 1)
Dose escalation willproceed sequentia llytoassess thefollowing SCdoses ofSHP681:
0.2mg/kg, 0.5mg/kg, 1mg/kg, 2mg/kg, and4mg/kg. After asingle administr ationofSHP681 
orplacebo ineach cohort, ifthedose isassessed assafeandtolerable during adose escalation 
meeting, thenext cohort willbeadministered aSCdose ofSHP681 atthenext higher dose level 
orplacebo. Allsubjects willhave theIPadmi nistered intheabdomen. During dose escalation, 
protocol defined dose levels may bereduced, repeated, discontinued, oranintermediate increase 
may beadded depending ontheoutcome oftheblinded safetydata review between dose 
escalations. Upon completion ofthese 5-dose cohorts, additional doses may bestudied based on 
emergent safetydata.
For non-commercial use only
Shire CONFIDENTIAL Page 41
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
MAD (Part 2)
The MAD part will not commence until results of a pharmacokinetic and safety  data review of 
SAD Cohort 1, SAD Cohort 2, and partial data from SAD Cohort 3 are available. Each cohort 
will receive SHP681 (or placebo) once weekl y for 5 weeks. After the first cohort has been 
administered 2 doses of SHP681 (or placebo) over 2 weeks and the dose is assessed as safe and 
tolerable during a dose escalation meeting, the next MAD cohort will commence. All subjects 
will have the I P administered i n the abdomen. Dose escalation will proceed sequentially  to 
include the following SC doses: 0.2 mg/kg, 0.5 mg/kg, 1 mg/kg, 2 mg/kg, and 4 mg/kg weekly.
An interim anal ysis was performed after the last subject from the 3rd MAD cohort completed the 
Day 39 visit, to determine the dose level of the 6th MAD cohort, and to assess safety and 
pharmacod ynamics .As of the interim anal ysis, TAK -681 was well- tolerated anddose-dependent 
. The absorption of TAK -681 follow ing SC 
dosing was slow, with absorption half-life 
ranging from 12.7 hours to 30.7 hours. The apparent 
clearance and volume of distribution were 0.105 L/hours and 14.3 L, respectively . The mean 
elimination half -life of TAK -681 ranged from 89.8 hours to 104 hours (ie, 3.7 day s to 4.3 days) 
across dose levels. TAK -681 PK properties were observed to be linear and time -independent. 
Using a noncompartmental anal ysis, the area under the concentration -time curve from time zero 
to infinity  of TAK -681 after multiple doses increased in a dose -proportional manner from 
0.2mg/kg to 1 mg/kg. Based on these results, a dose of 4 mg/kg SHP681 (or pla cebo) every  
2weeks over a 6- week period (3 doses) was nominated for the 6th MAD cohort. 
During dose escalation, protocol defined dose levels may be reduced, repeated, discontinued, or 
an intermediate increase may be added depending on the outcome of the blinded saf etydata 
review between dose escalations. 
3.1.2 Screening and Treatment Period
SAD (Part 1)
The SAD portion of the study will consist of a screening period of up to 28 d ays and one 
treatment period of 29 d ays. A total of 8 overnight st ays are require d for the SAD portion of the 
study.
The first dose will occur within 28 d ays of screening. Subjects will be admitted to the clinical 
research center (CRC) on Day  -1 and randomized to SHP681 or placebo on Day -1or the 
morning of Day1 as indicated in Figure 1. Subjects will not participate in mo re than 1 treatment 
cohort.
Safety andtolerability will be assessed bytreatment- emergent AEs (TEAEs), vital signs, 
electrocardiogram (ECG) findings, and clinical laboratory evaluations.
Blood samples for pharm acokinetic ana lysis of SHP681 will be collected through 672 hours post 
dose in each dosing period. The last study visit is scheduled at Day 29 and will include final 
safetyassessments; there will be no further follow up. Additional ly, blood draws for 
determination of anti -drug antibodies (ADAs) and neutralizing antidrug antibody (nADA) will be 
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 43
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
TheStudyCompletion Date is defined as the date the LAST subject, completes their final 
protocol -defined assessments.
Please note that this includes the last visit or contact, whichever is later. The Stu dyCompletion 
Date is used to ascertain timing for study results posting and reporting.
3.3 Sites and Regions
This study will be conducted at 1 CRC in the United States.
For non-commercial use only
Shire CONFIDENTIAL Page 44
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
4.STUDY POPULATION
Each subje ct must participate in the informed consent process and provide written informed 
consent before an y procedures specified in the protocol are performed.
4.1 Inclusion Criteria
The subject will not be considered eligible for the study  without meeting all of the criteria below. 
Subjects cannot be randomized before all inclusion criteria (including test results) are confirmed.
1.Abili ty to voluntari lyprovide written, signed, and dated informed consent t o participate 
in the study.
2. An understanding, ability, and willi ngness to full y comply  with study  procedures and 
restrictions.
3.Age 18 -50 inclusive at the time of consent. The date of signature of the informed consent 
is defined as the beginning of the screening period. This inclusion criterion will only  be 
assessed at the first screening visit.
4.Male, or non- pregnant, non -lactating female who agrees to comply  with any  applicable 
contraceptive requirements of the protocol or females of non- childbearing potential.
5.Considered “healthy ” by the investigator. Healthy  status is defined by  absence of 
evidence of an y active or chronic disease or condition based on a detailed medical and 
surgical history , a complete phy sical examination including vital signs, 12- lead ECG, 
hematology , blood chemistry , and urinal ysis.
6.Body mass index between 18.0 kg/m² and 30.0 kg/m² inclusive with a body weight 
50-100 kg (110 -220 lbs). This inclusion criterion will only be assessed at the first 
screening visit.
4.2 Exclusion Criteria
Subjects are excluded from the study if any of the following exclusion criteria are met:
1.History ofanyhematological, hepatic, respiratory , cardiovascular, renal, neurological or 
ps
ychiatric disease, gall bladder removal, or current or recurrent disease that could affect 
the action, absorption, or disposition of the investig ational product, or clinical or 
labor atoryassessments.
2.Current or relevant history  of phy sical or ps ychiatric illness, any medical disorder that 
may require treatment or render the subject unlikely  to full y complete the study, or an y 
condition that presen ts undue risk from the investigational product or procedures.
3.Known or suspected intolerance or hypersensitivity to the investigational product(s), 
closely -related compounds, or any  of the stated ingredients.
4.Significant illness, as judged b y the investig ator, within 2 weeks of the first dose of 
investigational product.
5.Known history  of alcohol or other substance abuse within the last y ear.
For non-commercial use only
Shire CONFIDENTIAL Page 45
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
6.Donation of blood or blood products (eg, plasma or platelets) within 60 days prior to 
receiving the first dose of inv estigational product.
7.Within 30 day s prior to the first dose of investigational product:
a.Have used an investigational product (if elimination half- lifeis<6days, otherwise 
5half-lives).
b.Have been enrolled in a clinical study .
c.Have had any substantial changes in eating habits, as assessed b y the investigator.
8.Use of DPP -4 inhibitors within 30 day s or 5 half -lives, whichever is greater, prior to 
administration of the investigational product.
9.Confirmed sy stolic blood pressure >139mmHg or <89mmHg, and diastolic blood 
pressure >89 mmHg or <49 mmHg.
10.Twelve -lead ECG demonstrating QTcF >450 msec at screening. If QTcF exceeds 
450msec, the ECG should be repeated 2 more times and the average of the 3 QTcF 
values should be used to determine the subject’s eligibility.
11.Positive screen for alcohol or illicit drugs at screening or Day  -1.
12.Male subjects who consume more than 21 units of alcohol per week or 3 units per day . 
Female subjects who consume more than 14 units of alcohol per week or 2 units per d a
y. 
(1 alcohol unit=1 beer or 1 wine (5 oz/150 mL) or 1 liquor (1.5 oz/40 m L)or 0.75 oz 
alcohol).
13.Positive HI V, HBsAg, or HCV antibody  screen.
14.Use of tobacco in an y form (eg, smoking or chewing) or other nicotine -containing 
products in an y form (eg, gum, pa tch). Ex -users must report that they  have stopped using 
tobacco for at least 30 days prior to receiving the first dose of investigational product.
15.Routine consumption of more than 2 units of caffeine per day  or subjects who experience 
headaches associated with caffeine withdrawal. (1 caffeine unit is contained in the 
following items: one 6 oz (180 mL) cup of coffee, two 12 oz (360 mL ) cans of cola, one 
12 oz cup of tea, three 1 oz (85 g) chocolate bars. Decaffeinated coffee, tea, or cola are 
not considered to contain caffeine).
16. Prior screen failure (unless Sponsor approval is given), randomization, participation, or 
enrollment in this study  or prior exposure to any  GLP -2 analogs
17.Unresected GI pol yp, known polyposis condition, or premalignant changes in the GI 
tract.
18.Any history  of malignancy  in the GI tract or treatment for any  other malignancy  in the 
previous 5 y ears.
19.Current use of an y medication (including over -the-counter, he rbal, or homeopathic 
preparations; with the exception of hormonal replacement therap y or hormonal 
contraceptives and occasional use of ibuprofen or acetaminophen and pre -approved 
medication for sedation or other medications required during or after the end oscopy ). 
Current use is defined as use within 14 day s of the first dose of investigational product.
20.Findings of subclinical hepatobiliary  disease, such as gallstones, on abdominal ultrasound 
at screening as determined by  the Investigator in consultation wi th the Medical Monitor.
For non-commercial use only
Shire CONFIDENTIAL Page 46
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
4.3 Restrictions
1.Subjects should refrain from taking DPP4 inhibitors through the course of the study .
2.Subjects should refrain from strenuous phy sical exercise 48 hours prior to admission to 
the CRC and during the in -house stay s at the CRC.
3. Subjects should refrain from alcohol 48 hours prior to admission to the CRC and during 
the in -house stay  at the CRC .
4.Subjects should refrain from use of tobacco or an y products containing nicotine within 
30 days of Day 1 of the first treatment period through the completion of the last treatment 
period.
5.Subjects should refrain from taking or regularl y using an y medication (including over-the 
counter multivitamin, herbal, or homeopathic preparations) with the exception of those 
listed in Section 5.2from 14 da
ys prior to receiving the first dose of the investigational 
product through the completion of the discharge assessments and procedures.
6. Subjects should refrain from foods or beverages containing caffeine/xanthine 48 hours 
prior to admission to the CRC and during the in -house stay  at the CRC.
7. Subjects will be required to follow standardized meal schedules and eat the meals 
provided b y the site while housed in the CRC. No outside food or beverages (including 
gum, mints, etc.) will be permitted. Menus wil l be identical for all subjects at the CRC. 
Subjects are not required to complete the entire meal but must meet their individual 
nutritional requirements to maintain stable weight. Copies of the menus will be provided 
to the sponsor for approval prior to the start of the study . 
4.4 Reproductive Potential
4.4.1 Female Contraception
Sexual lyactive females of childbea ring potential should be using an acceptable form of 
contraception. Females of childbearing potential must be advised to use acceptable 
contraceptives th roughout the study period and for 30 d
ays following the last dose of 
investigational product. If hormona l contraceptives are used, they should be administered 
according to the package insert. Females of childbearing potential who are not curren tlysexual ly
active must agree to use acceptable contraception, as defined below, if they become sexually  
active du ring the period of the study and 30 day s following the last dose of investigational 
product.
Female subjects should be either:
Medically  confirmed postmenopausal surgicall y sterile (having undergone one of the 
following surgical acts: hy sterectom y, bilateral tubal ligation, bilateral oophorectom y or 
bilateral salpingectom y) and at least 6 weeks post -sterilization, or
Females of childbearing potential with a negative serum beta -human chorionic gonadotropin 
(
β-hCG) pregnancy  test at screening and negative urine pregnancy  test on Day  -1. Females of 
childbearing potential must agree to abstain from sexual activity  that could result in 
pregnancy  or agree t o use acceptable methods of contraception.
For non-commercial use only
Shire CONFIDENTIAL Page 47
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Acceptable methods of contraception are:
Intrauterine devices plus condoms
Double-barrier methods (eg, condoms and diaphragms with spermicidal gel or foam)
Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized for at 
least 30 day s prior to the first dose of investigational product, plus condoms. Note: If subject 
becomes sexually  active during the study , they  should use one of the other acceptable 
methods noted above in addition to the hormonal contraceptive until it has been stabilized for 
30 day s.
4.4.2 Male Contraception
Male subjects must be advised to use acceptable contraceptives throughout the study period 
andfor 3 months following the last dose of investigational product. Male subjects must be 
advised not to donate sperm during the course of the study  and within 3 months of the last dose 
of investigational product. The acceptable method of contracept ion for male subjects is a 
doubl
e-barrier method (eg, condom with spermicidal ge l or fo am).
4.5 Discontinuation of Subjects
A subject may withdraw from the study atanytime for a nyreason without prejudice to their 
future medical care by the physician or at the institution. The investigator or sponsor may  
withdraw the subject at any time (eg, in the interest of subject safet y). The investigator is 
encouraged to discuss withdrawal of a subject from investigational product with the medical 
monitor when possible.
If investigational product is discontinued, regardless of the reason, the early withdrawal 
evaluations listed in are to be performed as completely as possible. Whenever possible, all 
discontinued subjects should also undergo the protocol- specified follow- up. Comments 
(spontaneous or elicited) or complaints made b y the subject must be recorded in the source 
documents. The reason for termination and date of stopping invest igational product must be 
recorded in the case report form (CRF) and source documents.
Randomized subjects who discontinue from the study maybe replaced at the sponso r’s 
discretion.
4.5.1 Reasons for Discontinuation
The reason for withdrawal must be determined by the investigator and recorded in the subject’s 
medical record and on the case report form (CRF). If a subject is withdrawn for more than 
1 reason, each reason shoul d be documented in the source document and the most clinically  
relevant reason should be e ntered on the CRF.
Reasons for discontinuation include but are not limited to:
Adverse event
Protocol deviation/violations
For non-commercial use only
Shire CONFIDENTIAL Page 48
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Withdrawal by  subject
Lost to follow -up
Other (Note: If “Other” is selected, then the specific reason will need to be recorded in the 
CRF)
4.5.2
Subjects “Lost to Follow-up” Prior to Last Scheduled Visit
A minimum of 3 documented attempts must be made to contact a ny subject lost to follo w-up at 
anytimep oint prior to the last scheduled contact (office visit or telephone contact). At least 1 of 
these documented attempts must include a written communication sent to the subject’s last 
known address via courier or mail (with an acknowledgement of receipt requ est) asking that they  
return to the site for final safet y evaluations and return any  unused investigational product.
4.5.3 Stopping Criteria for Dose Escalation
Dose escalation will not continue to the next planned dose/cohort if a ny of the following criteria 
aremet:
A serious adverse event (SAE) related to active drug (according to Investigator assessment) 
occurs in 1 or more subjects receiving active drug. No further subjects will be enrolled or 
dosed until further evaluation of the available data is made by the medical monitor and 
investigator to determine whether to stop or proceed with the study . Following a safet y 
review of the event, study  enrollment or dosing of currentl y enrolled subjects may be 
restarted if the medical monitor and the investigator det ermine that it is safe to proceed with 
the study .
Two or more subjects experience a treatment emergent adverse event (TEAE) of National 
Cancer Institute Common Terminology  Criteria for Adverse Events (CTCAE v5.0) 
Grade 3or higher in the same sy stem organ class (SOC).
If 2 or more subjects experience a treatment emergent adverse event (TEAE) of at least 
moderate severit y (such as National Cancer Institute [NCI ] Common Terminology  Criteria 
for Adverse Events [CTCAE v5.0] Grade 3 or higher) in the same s ystemorgan class (SOC).
Individual Stopping Criteria
Individual subjects should be discontinued if a nyof the following laboratory findings are 
observed:
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 8 × upper limit of 
normal (ULN)
AST or ALT > 5 × ULN for 2 weeks;
AST or ALT > 3 × ULN and either total bilirubin > 2 × ULN or international normalized 
ratio (INR) > 1.5;
For non-commercial use only
Shire CONFIDENTIAL Page 49
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
AST or ALT > 3 × ULN with sy mptoms consistent with hepatic disease or injury  
(e.g., fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash and/or 
eosinophilia >5%)
Any other drug related event occurs in subjects receiving active drug and is deemed to pose 
an unacceptable risk to subjects by  the investigator or medical monitor after further 
evaluation.
Dosing will be discontinued in an individual subject if that subject has a laboratory  
abnormality  or TEAE of CTCAE v5.0 Grade 3 or higher that is considered possibly  related to 
study  drug b y the investigator.
Should any of the apparent stopping criteria be met, the data under examination will be 
unblinded to ensure the c riteria have been met with respect to those subjects receiving active 
drug. The Shire Medical Monitor and/or principal investigator can request unblinding of the data 
at any time in order to further evaluate a possible saf etyconcern for an individual subject or 
entire cohort.
In case one of these dos e-limiting events occurs, it will be assumed that the minimum intolerable 
single dose or multiple doses has been reached. Further once-weekl y dosing will be at a dose, 
determined b
y theShire Medical Monitor and the principal investigator, below the minimum 
intolerable on ce-week lydose and when needed in consultation with the Shire Saf etyOfficer.
For non-commercial use only
Shire CONFIDENTIAL Page 50
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
5.PRIOR AND CONCOMITAN T TREATMENT
5.1 Prior Treatment
Prior treatment includes all treatment (including but not limited to herbal treatments, vitamins, 
non-pharmacological treatment such as psychotherap y as appropriate) received within 30 d ays 
(or pharmacokinetic equivalent of 5 ha lf-lives, whichever is longe r)of the date of first dose of 
investigational product. Prior treatment information must be recorded on the appropriate source 
documentation.
5.2 Concomitant Treatment
Concomitant treatment refers to all treatment taken between the dates of the first dose of 
investigational product and the last study  visit (or last contact with the subject, whichever comes 
first), inclusive. Concomitant treatment information must be recorded on the appropriate source 
documentation.
5.2.1 P ermitted Treatment
Subjects should refrain f rom taking an y medications (excluding those medications listed below) 
during the course of the study . Any medication which is considered necessary for the subject’s 
safetyand well -being may be given at the discr etion of the investigator. The administratio n of all 
medications (including investigational products) must be listed on the appropriate source 
documentation.
Medications permitted during the stud y are listed below:
Hormonal contraceptives for females of childbearing potential administered according to the 
package insert (see Section 4.4.1)
Hormone replacement therap y
Occasional use of ibuprofen or acetaminophen
5.2.2 Prohibited Treatment
Refer to S ection 4.3on restriction s for prohibited treatment.
For non-commercial use only
Shire CONFIDENTIAL Page 51
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
6.INVESTIGATIONAL PROD UCT
6.1 Identity of Investigational Product
The test product is SHP681 which will be provided in vials.
The reference/comparator product is a placebo which will be provided in vials. Additional 
information relate d to SHP681, including preparation and administration, is provided in the 
current SHP681 investigator brochure, and in an investigational prod uct preparation and 
administration manual that will be provided.
6.1.1 Blinding the Treatment Assignment
This is a rando mized, doubl e
-blind, placebo -controlled stud y. The actual treatment given to 
individual subjects is determined b y a randomization schedule. The associated treatment 
assignments giving details of individual subject treatment are in the form of vendor 
random ization schedule held at the investigational site which will be provided by the biostatistics 
vendor.
The randomization code will be sent to the unblinded dispenser at the site in a password 
protected file. This code will be opened by the unblinded dispenser and will be kept in a sealed 
envelope under locked conditions.
The investigator should assign the responsibility of unblinded dispenser to a person who will not 
participate in the evaluation of an y stud y subject. This permits all other participants to remain 
blinded. A member of the staff of the CRU or clinical pharmacy should fulfill this role and 
should be fully trained in the relevant aspec tsofthestudy. His/her role should be documented on 
the site’s delegation of authority log. The unblinded dispenser may not administer the 
investigational product to study subjects. The unblinded dispenser must give the investigational 
product to the investigator or designee for administration. The unblinded dispenser will draw up 
the dose into a s yringe andapply a colored wrap to the dosing s yringe(s) to ensure blinding, as 
the active investigational product has a yello w-brown tinge compared to the pl acebo. The 
unblinded dispenser may not administer the investigational product to study subjects. Contact 
between t he unblinded dispenser and stud y subjects should be kept to a minimum. The 
investigator, stu dy coordinator, andanystudy participants other t han the unblinded dispenser 
must not be allowed to know the investigational product assigned to a ny study subject and must 
not be allowed to see the randomization doe, investigational product containers, or treatment 
records. For emergency circumstances, please see Section 
6.2.3.
Aside from unblinding for the interim anal ysis, the treatment assignment must not be broken 
during the stu dy except in emergency  situations where the identification of the investigational 
product is required for further treatment of the subject(s) or to assess an ysafety,tolera bility, or 
pharmacokinetic questions based on the safe ty revie w.
Treatment assignments in the SAD cohorts and the first 3 MAD cohorts will be unblinded for an 
interim analy sis after the last subject in the 3rd MAD cohort completes the Day  39 assessments.
For non-commercial use only
Shire CONFIDENTIAL Page 52
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Each vial of SHP681 and placebo will be assigned a unique packa ging identification number. 
When a vial of SHP681 or placebo is assigned to a subject, the packaging identification number 
will be recorded in the drug accountabili ty records. Each subject will be assigned a specific vial 
or multiple vials of investigation al product.
6.2 Administration of Investigational Product(s)
6.2.1 Allocation of Subjects to Treatment
This is a randomized, double- blind, placebo -controlled stu dy.
Subject numbers are assigned to all subjects as they consent to take part in the stu dy. Within each 
site (numbered uniqu elywithin a protocol), the subject number is assigned to subjects according 
to the sequence of presentation for study participation. This will be a 4- digit number starting at 
0001.
The actual treatment given to individual subjects is determined by a randomization schedule. The 
randomization number represents a unique number representing study  portion (SAD/MAD) as 
well as cohort and corresponds to investigational product allocated to the subject. This 
randomization number will be assign ed prior to dosing after eligibility  has been determined.
For the SAD portion Cohort 1, this unique 4 -digit randomization number will be assigned as 
follows:
Cohort Patient/Order of Randomization Randomization #
Cohort 1 First Patient Randomized in the Fi rst SAD Cohort 1101
Cohort 1 Second Patient Randomized in the First SAD Cohort 1102
Cohort 1 Third Patient Randomized in the First SAD Cohort 1103
Cohort 1 X Patient randomized in the First SAD Cohort 110X
For the MAD portion Cohort 1, this unique 4- digit randomization number will be assigned as 
follows:
Cohort Patient/Order of Randomization Randomization #
Cohort 1 First Patient Randomized in the First MAD Cohort 2101
Cohort 1 Second Patient Randomized in the First MAD Cohort 2102
Cohort 1 Third Patient Randomized in the First MAD Cohort 2103
Cohort 1 X Patient randomized in the First MAD Cohort 210X
For non-commercial use only
Shire CONFIDENTIAL Page 53
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
If a randomization number is allocated incorrectly the study monitor must be notified as soon as 
the error is discovered. Once a randomization number has been assigned, that number must not 
be used again if, for example, a subject is withdrawn from the st udy.
Investigational product packaging identification numbers, separate from randomization 
numbers/unique identifiers, may  also be assigned to s ubjects for specific treatment assignment as 
dictated b y the study. In these cases, the same investigational product packing identification 
number may  not be assigned to more than 1 subject.
6.2.2 Dosing
After satisfy ing all screening and entry  criteria, SHP681o r placebo will be administered in the 
abdomen to all subjects according to the following schedule:
SAD portion of the study
The plan is to enroll 30 subjects in 5 cohorts. Each cohort will include 6 subjects. Subjects will 
be randomized within each cohort such that 5 subjects receive SHP681 and 1 subject receives 
placebo. After a single administration on Day  1 of each treatment period of SHP681 or placebo 
in each cohort, if the dose is assessed as safe and tolerable during a dose escalation meeting, the 
next cohort will be administered a SC dose of SHP681 at the next higher dose level or placebo.
Dose escalation will proceed sequentially to assess the following SC doses of SHP681: 
0.2mg/kg, 0.5 mg/kg, 1 mg/kg, 2 mg/kg, and 4 mg/kg. During dose escalation, p rotocol defined 
dose levels may be reduced, repeated, discontinued, or an intermediate increase may be added 
depending on the outcome of the blinded saf ety data review between dose escalations.
MAD portion of the study
The plan is to enroll 72 subjects within 6 MAD cohorts. Each cohort will include 12 subjects. 
Subjects will be randomized within each cohort such that 10 subjects receive SHP681 and 
2subjects receive placebo. Subjects in the first 5 MAD cohorts will receive SHP681 (or placebo) 
once weekly for5weeks, on Day 1, 8, 15, 22 and 29. After the first cohort has been administered 
2 doses of SHP681 (or placebo) over 2 weeks and the dose is assessed as safe and tolerable 
during a dose escalation meeting, the next MAD cohort will commence. Dose esca lation will 
proceed sequential ly to include the following SC doses: 0.2 mg/kg, 0.5 mg/kg, 1 mg/kg,
2mg/kg, and 4 mg/kg. Subjects in the 6th MAD cohorts will receive 4 mg/kg SHP681 (or 
placebo) once every  2 weeks, on Day  1, 15, and 29. 
During dose escalat ion, protocol defined dose levels may be reduced, repeated, discontinued, or 
an inter mediate increase may be added depending on the outcome of the blinded saf ety data 
review between dose escalations.
6.2.3 Unblinding the Treatment Assignment
Treatment assignments in the SAD cohorts and the first 3 MAD cohorts will be unblinded for an 
interim analy sis after the last subject in the 3rdMAD cohort completes the Day  39 assessments.
For non-commercial use only
Shire CONFIDENTIAL Page 54
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Aside from unblinding for the interim anal ysis, the treatment assignment mus t not be broken 
during the st udyexcept in emergency situations where the id entification of the investigational 
product is required for further treatment of the subject. The investigator should contact the 
medical monitor as soon as possible after the blin d has been broken.
In the event that the treatment assignment is broken, the date, the signature of the person who 
broke the code and the reason for breaking the code are recorded on the source documents. Upon 
breaking the blind, the subject is withdrawn f rom the stud y, but should be followed up for safe t y
purposes. Any code -breaks that occur must be reported to the sponsor and contract research 
organization (CRO). Code- break information is held by the unblinded dispenser at the site.
6.2.4 Labeling
Labels contai ning study information and pack identification are applied to the investigational 
product(s) container.
All investigational product is labeled with a minimum of the protocol number, medication 
identification number, dosage form (including product name and quantity in pack), directions for 
use, storage conditions, batch number, an d/or packaging reference, the statements "For clinical 
trial use on l
y," and/or "CAUTION: New Drug -Limited by Federal (or US) Law to 
Investigational Use," and "Keep out of reach of children," and the sponsor's name and address.
Space is allocated on the la bel so that the site representative can record a unique subject 
identifier and date of dispensation.
Additional labels (eg, those used when dispensing marketed product) ma y, on a case-by- case 
basis, be applied to the investigational product in order to sat isfylocal or institutional 
requirements, but must not:
Contradict the clinical study label
Obscure the clinical study label
Identify  the study  subject by  name
Additional labels m aynot be added without the sponsor’s prior full agreement.
6.2.5 Packaging
One vi al of investigational product is packaged in one labeled carton.
Changes to sponsor- supplied packaging prior to dosing may not occur without full agreement in 
advance by thesponsor.
6.2.6 Storage
The investigator has overall responsibility for ensuring that investigational product is 
stored in asecure, limit ed-access location. Limited responsibilit y may be delegated to 
the pharmacy ormember of the stu dyteam, but this delegation must be documented. 
For non-commercial use only
Shire CONFIDENTIAL Page 55
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Investigational products are distributed by the unblinded dispenser or nominated member 
ofthestudyteam.
Investigational product must be stored in accordance with labeled storage conditions. 
Temperature monitoring is required at the storage location to ensure that the investigational 
product is maintained within an established temperature range. The investigator is 
responsible for ensuring that the temperature is monitored throughout the duration of the study 
and that records are maintained; the temperature should be monitored continuously  by using 
either an in -house s ystem, a mechanical recording device such as a calibrated chart recorder, or 
by manual means, such that both minimum and maximum thermometric val ues over a specific 
time period can be recorded and retrieved as required. Such a device (ie, certified min/max 
thermometer) would require manual resetting upon each recording. The sponsor must be notified 
immediately  upon discovery  of an y excursion from t he established range. Temperature 
excursions will require site investigation as to cause and remediation. The sponsor will determine 
the ultimate impact of excursions on the investigational product and will provide supportive 
documentation as necessary . Under no circumstances should the product be dispensed to subjects 
until the impact has been determined and the product is deemed appropriate for use b y the 
sponsor.
The sponsor should be notified immediately  if there are an y changes to the storage area of the 
investigational product that could affect the integrity  of the product(s), eg, fumigation of a 
storage room.
6.3 Drug Accountability
Investigators will be provided with sufficient amounts of the investigational product to carry out 
this protocol for the agreed-upon number of subjects.
Theinvestigator ordesignee will acknowledge receipt of the investigational product, 
documenting shipment content and condition. Accurate records of all investigational product 
dispensed, used, returned, and/or destr oyed must be maintained as detailed further in this section.
The investigator has overall responsibility for administering investigational product. Where 
permissible, tasks may be delegated to a qualified designee (eg, a pharmacist) who is adequat ely 
trained in the protocol and who works under the direct supervision of the investigator. This 
delegation must be documented in the applicable study delegation of authority form.
The investigator or his/her designee (as documented by the investigator in the applicable study 
delegation of authority form) will administer the investigational product only to subjects 
included in this study following the procedures set out in the study protocol. Each subject will be 
given onl y the investigational product car r ying his/her tr eatme nt assignment. All administered 
medications will be documented on the CRFs and/or other investigational product record. 
Noinvestigational product stock or returned inventory  from a Shi re-sponsored study may be 
removed from the site where origina llyshipped without prior knowledge and consent by the
sponsor. If such transfer is authorized by the sponsor, all applicable local, state, and national laws 
must be adhered to for the transfer.
For non-commercial use only
Shire CONFIDENTIAL Page 56
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
With the written agreement of the sponsor, at the end of the stu dyall unused stock, and 
empty /used investigational product packaging may be destr oyed at the site or a local facili ty. In 
this case, destruction records identify ing what was destr oyed, when and how, must be obtained 
with copies provided to the sponsor. Destruction of investigational produ ctsmust be in 
accordance with local, state, and national laws.
Based on entries in the site drug accountability forms, it must be possible to reconcile 
investigational products delivered with those used and returned. All i nvestigational products 
must be accounted for and all discrepancies investigated and documented to the sponsor’s 
satisfaction.
6.4 Subject Compliance
Compliance must be assessed by observation of dosing by the investigator or designee. The 
investigator/nominated person will record details on the drug accountability log(s) and/or source 
documents. In addition, details of the dosing time (time and date) will be captured in the 
appropriate CRF.
6.5 Retention of Bioavailability and Bioequivalence Te sting Samples
Not applicabl e.
For non-commercial use only
Shire CONFIDENTIAL Page 57
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
7.STUDY PROCEDURES
7.1 Study Schedule
See the Study  Schedules forstudy procedures to be followed in the study.
The following “priorit y order” will be in effect when more than 1 procedure or assessment is 
required at a particular timepoint.
Spontaneous or solicited adverse event (AE) reporting
Vital signs
Electrocardiogram (ECG)
P
hysical examination

Blood sampling for ADA and nADA
Pharmacokinetic blood sampling
Clinical laboratory tests
Pregnancy  testing
NOTE: Blood sampling for PK evaluation must be performed at the precise protocol -scheduled 
time. Actual sampling tim e(s) must be accurate ly recorded in the source document and 
appropriate CRF. Pharmacokinetic blood collec tion must not deviate from the nominal collection 
time set forth in the protocol by  more than ±5 minutes from samples drawn within 4 hours after 
the first dose or b y more than ± 15 minutes for samples drawn be tween 4 hours and 24 hours after 
the first dose. Samples drawn bey ond study  day 2 can notdeviate b y more than 10% of the 
specified time from the first dose.
7.1.1 Screening Period
For both SAD and MAD part of the stud y, screening procedures must be completed within 
28 day s prior to receiving the first dose of investigational product. All sc reening assessments and 
procedures are to be performed by the principal investigator or a qualified designee. See the 
Study  Schedules for a complete list of screening procedures to be performed.
Written , signed, and dated informed consent from each subject prior to the performance of a
ny 
study-related procedures must be obtained by the principal investigator or a designee. A copy of 
the signed informed consent must be given to the subject and/or subject’ s parent/LAR for their 
records.
7.1.1.1 Screening Failure
A screen failure is a subject who has given informed consent and failed to meet the inclusion 
and/or met at least 1 of the exclusion criteria and has not been randomized and/or enrolled or 
administered inve stigational product(s).
For non-commercial use only
Shire CONFIDENTIAL Page 58
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Subjects who fail to meet all inclusion/exclusion criteria will not be permitted to be rescreened 
for the stud y at an y point.
Eligible subjects who meet all inclusion/exclusion criteria but are unable to participate in the 
study  due to scheduling conflicts/timing may  be rescreened based on investigator discretion and 
sponsor approval should their availability  to participate fall outside the screening window. In 
these cases, a new subject number must be assigned for each subject who i s rescreened and a 
new informed consent form must be signed.
7.1.2 Treatment Period
SAD (Par t 1)
7.1.2.1 Admission to the CRC (Day -1)
Following the screening visit, eligible subjects will return to the CRC on Day - 1 of the stu dy. See
the Study  Schedules for a list of procedures and assessments to becompleted upon admission to 
the CRC. Subjects who 
successfull ycomplete the pre- admission procedures and assessments will 
be admitted to the CRC on Day -1 and randomized and assigned a randomization number on Da y
-1 or Day1 as described in Section 6.2.1.
7.1.2.2 Treatment Period (Day 1 through Day 29)
Subjects will be admitted to the CRC after eligibility  is confirmed on Day  -1. Subjects will be 
confined at the CRC from Day  -1 until after completion of the assessments on Day  8 as indicated 
in the Study  Schedules . SHP681 or placebo will be administered on Day  1 of the treatment 
period for each cohort. On Day  8 subjects will be discharged from the CRC. From Day  11 to 
Day 29 the subjects will be back at the CRC for outpatient visits to complete the study  
procedures, safety  and pharmacokinetic assessments as indicated in the 
Study  Schedules .
MAD (Part 2)
7.1.2.3 Admi ssion to the CRC (Day -1)
Following the screening visit, eligible subjects will return to the CRC on Day  -1 of the stud y. 
Seethe Study  Schedules for a list of procedures and assessments to be completed upon 
admission to the CRC. Subj ects who successfully  complete the pre -admission procedures and 
assessments will be admitted to the CRC on Day  -1 and randomized and assigned a 
randomization number on Day  -1 or Day  1 as described in Section 6.2.1.
7.1.2.4 MAD Cohorts 1 -
5 Treatment Period (Day 1 t hrough Day 57)
Eligible subjects will be confined to the CRC from the morning of Day  -1 until completion 
ofallprocedures and assessments on Day  4. SHP681 or placebo will be administered on 
Day 1of the treatment period for each cohort. On Day  4 subjects will be discharged from the 
CRC. They  will then be readmitted in the CRC on Day  7, Day  14, Day  21 and Day  28 and 
discharged from the CRC respectivel y on Day 10, Day 18, Day 24 and Day 36 after completion 
of the assessments as indicated in the Study  Schedules . From Day 39toDay 57thesubjects will 
For non-commercial use only
Shire CONFIDENTIAL Page 59
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
return to the CRC for outpatient visits to complete the study  procedures, safety  and 
pharmacokinetic assessments as indicated in the Study  Schedules .
7.1.2.5 MAD Cohort 6 Treat ment Period (Day 1 through Day 57)
Eligible subjects will be confined to the CRC from the morning of Day  -1 until completion of all 
procedures and assessments on Day  4. SHP681 or placebo will be administered on Day  1 of the 
treatment period for each cohort. On Day  4 subjects will be 
dischar ged from the CRC. They  will 
then be readmitted in the CRC on Day  14 and Day 28 and discharged from the CRC, 
respectivel y, on Day  18 and Day  36 after completion of the assessments as indicated in the 
Study Schedules. From Day  39 to Day 57 the subjects will return to the CRC for outpatient visits 
to complete the study  procedures, safet y and pharmacokinetic assessments as indicated in the 
Study  Schedules .
7.1.3 Follow -up Period
There will be no further follow up.
7.1.4 Additional Care of Subjects after the Study
No aftercare is planned for this study.
7.2 Study Evaluations and Procedures
7.2.1 Demographic and Other Baseline Characteristics
Demographic characteristics such as date of birth, sex, weight, height and body mass index will 
be collected according to the Study  Schedules .
7.2.2 Safety
The name and address of each third-part y vendor (eg, clinical laborato ry)used in this study will 
be maintained in the investigator’s and sponsor’s files.
Actual safety assessment tim es will be monitored and recorded. The sponsor’s expectation is 
thatthe investigator will ensure that every effort is made to perform all assessments at the 
precise protocol -scheduled time. Any safety assessment that deviates from the scheduled 
assessment time set forth in the protocol by more than ±15 minutes will be considered a protocol 
deviation.
An AE is an y unfavorable and unintended sign, ie, any c linical ly significant worsening from 
baseline of an abnormal laboratory finding, symptom, or disease temporally associated with the 
use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product (ICH Guidance E2A 1995). Treatment emergent AEs (TEAEs) are 
adverse events that occur after initiation of either the investigational product or placebo (see 
Section 8 for more information).
For non-commercial use only
Shire CONFIDENTIAL Page 60
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
7.2.2.1 Medical and Medication History
A complete medical and medication history , as well as demogr aphic information, will 
be performed at the screening visit/timepoints described in the Study  Schedules bya 
qualified licensed phy sician, p hysician’s assistant, nurse practitioner, or a delegated study  
coordinator/assistant. The medical history willbereviewed andrecorded, including:
Date of birth
Sex
Race and ethnicity
Recent ingestion of medication (30 day s prior to entering the screening period)
History ofrespirator y, cardiovascular, renal, gastrointestinal, hepatic, endocrine, 
hematological, neurological, ps ychiatric, and other diseases
Smoking habits
7.2.2.2 Physical Exa mination (Including Height and Weight)
Complete or abbreviated p h
ysical examinations will be performed as specified at the time points 
described in the Study  Schedules bya qualified licensed p hysician, p hysician’s assistant, or nurse
practitioner.
The complete phy sical examinations will include a review of the following body systems:
General appearance
Skin
Head, ey es, ears, nose, and throat
Spine/neck/thy roid
Musculoskeletal
Respiratory
Cardiovascular
Neurological
Abdomen (including liver and kidney s)
Abnormalities identified at the screening visit will be documented in the subject’s source 
documents and on the medical history CRF. Changes after the screening visit that are considered 
clinically significant b
y the investigator will be captured as AEs on the AE CRF page.
7.2.2.3 Adverse Event Collection
At each stud y visit, subjects will be questioned in a general way to ascertain if AEs have 
occurred since the previous visit (eg, “Have you had any health problems since your last visit?”). 
For non-commercial use only
Shire CONFIDENTIAL Page 61
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Adverse events are collected from the time informed consent is signed. (Please refer to Section 8, 
Adverse and Serious Adverse Events Assessment.)
7.2.2.4 Vital Signs
Blood Pressure and Pulse Rate
Blood pressure and pulse rate will be measured at times specified i nthe 
Study  Schedules of this 
protocol. Additional blood pressure and pulse rate measurements may be performed, as 
determined b y the investigator, in order to ensure appropriate monitoring of subject safety and 
accurate recording of vital sign measurements. A ny changes from baseline which are deemed 
clinically  significant by the investigator are to be recorded as an AE.
The same method for obtaining blood pressure measurement ( auscultatory or oscillometric) 
should be used throughout the study for all subjects (and documented). In addition, the 
conditions of vital sign measurements should be controlled and as consistent as possible during 
thestudy, in order to minimize external v ariability of the readings. It is advised that 
measurement s be collected at a comfortable room temperature with little to no background noise, 
using the same (appropriate ly sized) cuff placed at the same location of the same arm during the 
study
.
The bladder deflation rate should be deflated (calibrated for oscillometric method or manually  by 
auscultatory  method) at a rate of 2- 3 mmHg/s (and the first and last audible sounds recorded as 
systolic and diastolic pressure) after at least 5 minutes of rest in the assumed position.
The cuff should have a bladder le ngth that is 80% and a width that is at least 40% of arm 
circumference (a length -to-width ratio of 2:1).
The subject should be asked to remove all clothing that covers the location of cuff placement. 
The subject should not have exercised or consumed caffei ne, alcohol, or nicotine within 
30 minutes of collection. The subject should be instructed to relax as much as possible for at 
least 5 minutes prior to collection. The subject should remain quiet during this time and through 
the measurement.
The subject should be sitting comfortabl y, with the legs uncrossed. The arm should be supported 
with a pillow, such that the middle of the cuff on the upper arm is at the level of the right atrium 
(approximately  halfway  between the bed and the level of the sternum).
At the screening visit, blood pressure should be compared between both arms. I f, after a single 
measurement is taken, there is a difference between arms in either s ystolic or diastolic blood 
pressure of >10 mmHg, the site will perform triplicate BP measuremen ts in each arm to 
determine the arm with the higher BP. The arm with the higher BP (based on the average of the 
3BP measurements for each arm) should be used for inclusion at screening, and the last of the 
3
measurements recorded in the eCRF as the screen ing BP. The same (right or left) arm with the 
higher blood pressure will be used throughout the study .
For non-commercial use only
Shire CONFIDENTIAL Page 62
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
One reading (seated s ystolic blood pressure/diastolic blood pressure- pulse) should be taken. The 
use of automated devices for measuring pulse rate is acc eptable, although, when done manually , 
pulse rate will be measured in the brachial/radial artery  for at least 30 seconds. When the timing 
of these measurements coincides with a blood collection, blood pressure and pulse rate should be 
obtained prior to the nominal time of the blood collection.
Body Temperature
Oral temperature should be taken by placing a digital thermometer under the tongue for at least 
30 seconds and the temperature reported in degr ees Celsius. Ty mpanic temperature may also be 
used.
7.2.2.5 Clini cal Laboratory Evaluations
All clinical laboratory  assay s will be performed according to the laboratory ’s normal procedures. 
Reference ranges are to be supplied by  the laboratory  and will be used to assess the clinical 
laboratory  data for clinical signific ance and out -of-range pathological changes. The investigator 
should assess out -of-range clinical laboratory  values for clinical significance, indicating if the 
value(s) is/are not clinically  significant or clinically  significant. Abnormal clinical laborato ry 
values, which are unexpected or not explained by  the subject’s clinical condition, may , at the 
discretion of the investigator or sponsor, be repeated as soon as possible until confirmed, 
explained, or resolved.
The following clinical laboratory  assessme nts will be performed:
Biochemistry
Blood samples (8.5 mL) for serum biochemistry  will be collected into a gel separator tube at the 
timepoints described in the Study  Schedules . The following parameters will be assessed:
Sodium
PotassiumPhosphorus
Total protein-hCGa
Glucose
Blood urea nitrogenTotal C O2(Bicarbonate)
Albumin
Creatinine Aspartate transaminase
Amy lase Lipase
Calcium Alanine transaminase
Chloride Gamma glutam yl transferase
Thyroid stimulating hormone (TSH) Free T3b
T3bThyroxine -binding Globulinb
T4bAlkaline phosphatase
Uric acid Total bilirubin
-hCG = beta -human chorionic gonadotropin
aFemales only
bThese parameters will only be calculated on Day 1, Day 8, and Day 15 for the SAD portion of the study. An additional 3.5 mL 
of blood will be collected from each subject on Days 1 and 8 for the assessment of TBG. T3, T4, and Free T3 will be assessed 
from t he 8.5 mL collected for the biochemistry. On Day 15, an additional 7 mL of blood will be collected from each subject for 
the assessment of T3, T4, Free T3, and TBG
For non-commercial use only
Shire CONFIDENTIAL Page 63
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Hematology
Blood samples (4 mL) for hematology will be collected into an EDTA 
(ethylenedia minetetraacetic acid) tube at the timepoints described in the Study  Schedules . The 
following parameters will be assessed:
Hemoglobin Total neutrophils (absolute) 
Hematocrit Eosinophils (absolute)
Red blood cells Monocy tes (absolute) 
Platelet count Basophils (absolute) 
White blood cell count; total and differential Lymphoc ytes (absolute)
Urinalysis
A urine sample for urina lysis will be collected at the timepoints described in the 
Study Schedules. The following parameters will be assessed:
pH Blood Nitrites
Glucose Ketones Leuko cyte esterase
Protein Bilirubin Specific gravi ty
Microscopic examination will be conducted if protein and/or blood is/are detected during 
urina lysis. At a minimum the microscopic examination will consist of red blood cells, white 
blood cells, casts, and bacteria.
7.2.2.6 Pregnancy Test
For all female subjects (regardless of reproductive potential status), a serum pregnancy testis 
performed at the screening visit, while urine pregnancy test will be performed at subsequent 
scheduled timepoints as indicated in the Study  Schedules ifpregnanc yis suspected; or on 
withdrawal of the subject from the study.
7.2.2.7 Drug and Alcohol Screen
A urine screen for drugs of abuse and alcoho l breath test will be performed at the timepoints 
described in 
the Study  Schedules . Additional drug and alcohol screens may be performed at the 
investigator’s discretion.
Urine samples are to be tested for amphetamines, barbiturates, benzodiazepines, cannabinoids, 
cocaine, methadone, opiate metabolite, and phencyclidine.
Results of urine drug and alcohol screens will be reviewed and verified bythestudy monitor but 
will not be collected in the CRF database.
For non-commercial use only
Shire CONFIDENTIAL Page 64
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Anypositive result for drugs of abuse or alcohol at screening or on Day -1 will exclude the 
subject from further participation in the study . If during the stu dy, the subject becomes positive 
for drugs of abuse (except ethanol <0.08 mg/dl or cannabinoids), the subject will be wit hdrawn 
from the stud y.
7.2.2.8 Serology Screen
At the screening visit, a blood sample of approximately 8.5 mL will be drawn into a serum 
separator tube to test for the presen ce of HIV, HBsAg, and HCV antibod y.
The test results must be confirmed negative prior to enrollment in the study. If a test result 
ispositive, the subject will be excluded from entering the st udy. Results of the virology
screen will be reviewed and verifi ed by the study monitor but will not be collected in the CRF 
database.
7.2.2.9 Electrocardiogram
Twelv e-lead ECGs will be performed at the times specified in the Study  Schedules .All ECGs 
will be performed using the equipment supplie d by the CRC.
The following parameters will be recorded on the appropriate CRF page: heart rate, PR, 
RR,QRS, and QT intervals. The QTcB and QTcF will be derived from the data in the 
database. The investigator’s assessment of the ECG tracing as normal or abnormal must 
be documented, and if abnormal, his/her determination of whether theabnormality is 
clinical lysignificant or not will be documented on the tracing and recorded in the source 
documentati on.
The subject should be asked to remove all clothing that covers the location of lead placement. 
The subject should not have exercised or consumed caffe ine, alcohol, or nicotine within 
30
minutes prior to collection. The subject must be resting in the supine position for at least 
5minutes prior to collecting the ECG.
In some cases, it may be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads are placed in the 
same positions each time in order to achieve precise ECG recordings.
Triplicate recording, including a 10-second rhy thm strip, will be obtained approximately  
2-4minutes apart for all assessments excluding the screening visit (wherein a single ECG 
assessment is required). Each ECG parameter obtained with the 3
assessments will be recorded 
in the CRF. The average of the triplicate ECG measurements collected at each nominal timepoint 
will be used for ana lysis. The 3 recordings should be immediately assessed as valid recordings 
and if not valid, they should be repeated in order to obtain a total of 3 valid recordings. Invalid 
recordings will not be entered in the CRF.
When triplicate ECGs are obtained: The average of the triplicate ECG measurements collected 
predose on Day 1 will serve as the subject’s baseline EC G.
For non-commercial use only
Shire CONFIDENTIAL Page 65
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
To ensure saf ety of the subjects, a qualified individual at the investigational site will make 
comparisons to baseline measurements.
If the QTcF interval (calculated online on site) is increased b y >45 msec from the baseline, or an 
absolute QTcF value is >500 msec for any scheduled ECG, then 2 additional ECGs will be 
collected, approximat ely 2- 4 minutes apart , to confirm the original measurement. 
Ifeither oftheQTcF values from these repeated ECGs remains above the threshold value 
(>45 msec increase from the baseline; or >500 msec), then a single ECG must be repeated at 
least hourly until QTcF values from 2 successive ECGs fall below the threshold value that 
triggered the repeat measurement. When triplicate ECGs are collected, the mean of the triplicate
measurements should be used to trigger the decision to collect follow -up ECGs.
If QTcF values remain above 500 msec (or >45 msec from the baseline) for >4 hours (or sooner 
at the discretion of the investigator) or QTcF intervals get progressiv elylonger, the subject 
should undergo continuous ECG monitoring. A cardiologist should be consulted ifQTcF 
intervals do not return to <500 msec (or to <45 msec above the baseline) after 8 hours of 
monitoring (or sooner at the discretion of the investigator). If amachine-read QTcF/QTcB value 
is prolonged, as defined above, repeat measurements may not benecessary if a qualified 
physician’s interpretation determines that the QTcF/QTcB values are in the acceptable range.
7.2.2.10 Abdominal Ultrasound
An abdominal ultrasound will be performed at the times specifie
d in the Study  Schedules .
7.2.3 Pharmacokinetic Procedures
The name and address of the bioanaly tical laboratory (ies) forthis studywill be maintained in the 
investi gator’s files at the/each site and in the Trial Master File at the sponsor. A laboratory  
manual fully describing the schedule and method of sample handling will be provided to the site. 
Actual pharmacokinetic blood sample collection times versus time of do sing will be monitored. 
The sponsor’s expectation is that the investigator will ensure that every effort is made to collect 
all pharmacokin etic blood samples at the precise protocol scheduled time but must record the 
actual clock time (AM/PM or 24- hr) of the sample collection. Pharmacokinetic blood collection 
must not deviate from the nominal collection time set forth in the protocol by  more than 
±5minutes for samples drawn within 4 hours after the first 
dose or by morethan ±15 minutes for 
samples drawn between 4 hours to 24 hours after the first dose. Samples drawn bey ond study  day 
2cannot deviate by more than ± 10% of the specified time from the first dose . Samples drawn 
outside these parameters will be considered a protocol deviation.
7.2.3.1 Blood Sample Collection and Handling Procedures
Blood samples will be collected at the time specified in the Study  Schedules to measure plasma 
concentrations of SHP681.
A full description of the PK blood collection, handling, storage, and shipping can be found in the 
laboratory manual.
For non-commercial use only
Shire CONFIDENTIAL Page 66
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Plasma sample tubes for bioanal ysis must be freeze r-safe and identified with freezer- safe labels 
provided b y the CRC. The labels will contain the following information:
Studynumber (SHP681-101)
Subject identifier
Treatment Dose and portion of the study (SAD or MAD)
Period
Nominal day (Day 1, Day 2, etc.)
Nominal time
Matrix identifier (plasma for PK)
Split (primary or backup or aliquot 1 or aliquot 2)
7.2.3.2 Shipment of Plasma Pha rmacokinetic Samples
All pharmacokinetic samples should be placed in a c ryo-box, doub le-bagged to contain leaks and 
packed with a sufficient quantity of dry ice to ensure that they remain frozen for at least 72 hours 
to allow for del a
ys in shipment. All applicable shipping regulations must be followed. Shipments 
should be scheduled so that no samples arrive on the weekend and should be shipped 
Monday -Wednesday  only . Samples should be transported to ensure that they arrive at the 
bioanaly tical laboratory  between the hours of 9:00 AM and 4:00 PM. The recipient and primary  
Shire contact must be notified by  telephone or e -mail when the samples are shipped, and they  
must be provided with the shipment tracking number.
Full directions for shipment of all PK samples, (along with the corresponding documentation) 
can be found in the laboratory  manual provided under separate cover.
Pharmacokinetic samples will be stored nominally at 
-70° C prior to and after anal ysis at the 
laboratory performing the assay  until sample disposal is authorized by  Shire.
7.2.3.3 Plasma Drug Assay Methodology
Plasma sample anal ysis will be performed according to the relevant Standard Operating 
Procedures at the contract bioana lytical lab.
Plasma concentrations will be measured using the most current validated bioanal ytical method. 
In addition, selected plasma samples may  be used to investigate incurred sample reproducibility  
(full details will be described in the bioanal ytical study  plan). The presence of other metabolites 
or artifacts may  be monitored or quantified as appropriate. Raw data will be stored in the archive 
of the designated bioanaly tical contract laboratory.
7.2.4 Pharmacodynamic Assessm ents
Not applicable.
7.2.5 Pharmacogenom ic Assessments
Not applicabl e.
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 68
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
7.2.7 Volume of Blood to be Drawn from Each Subject
Table 12 Volume of Blood to be Drawn from Each Subject
SAD (Part 1 ofthestudy)
Assessment Sample Volume (mL)Number of
SamplesTota lVolume (mL)
Pharmacokinetic sample sa7 14 98
ADA andnADA samples 6 2 12
HBsAg, HIV, HCV 8.5 1 8.5
Safety Biochemistry and 
-hCGb8.5 6 51
Hematology 4 6 24
Thyroid Panelc3.5 4 14
Total mL 207.5
MAD Cohorts 1 -5(Part 2 ofthestudy)
Pharmacokinetic sample sa7 22 154
ADA andnADA samples 6 7 42
HBsAg, HIV, HCV 8.5 1 8.5
Safety Biochemistry and 
-hCGb8.5 13 110.5
Hematology 4 13 52
6 3 18
Total mL 385
MAD Cohort 6 (Part 2 ofthestudy)
Pharmacokinetic sample sa7 20 140
ADA andnADA samples 6 7 42
HBsAg, HIV, HCV 8.5 1 8.5
Safety Biochemistry and 
-hCGb8.5 13 110.5
Hematology 4 13 52
6 3 18
Total mL 371
-hCG=bet a-human chorionic gonadotropin; HBsAg=hepatitis B surface antigen; HCV=hepatitis C virus; HIV=human 
immunodeficiency virus
aIf a catheter is used, the first mL is to be discarded; then take 6 mL into appropriate tube for pharmacokinetic sample. A t otal of
7 mL of blood drawn has been used in determinatio n of sample volume.
b-hCG testing for females only.
cThyroid Panels consist of T3, T4, Free T3, TSH, and Thyroxine -binding globulin (TBG); on Day 1 and Day 8, one 3.5 mL tube 
will be collected. On Day 15, two 3.5 mL tubes will be collected.
During this stud y, it is expected that approximately 207.5 mL of blood in the SAD portion of the 
study, and approximately 385 mL of blood in the MAD part will be drawn from the subjects, 
regardless of sex.
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood 
to be drawn may varyaccording to the instructions provided by the manufacturer or laboratory  
for an individual assessment; however, the total volume drawn over the course of the stud y 
should be approximately 207.5 mL and 385 mL for the SAD subjects and MAD subjects, 
respectiv
ely. When more than 1 blood assessment is to be done at the timepoint/period, if they  
require the same type of tube, the assessments may be combined.
For non-commercial use only
Shire CONFIDENTIAL Page 69
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
8.ADVERSE AND SERIOUS ADVERSE EVENTS ASSES SMENT
8.1 Definition of Adverse Events, Period of Observation, Recording of Adve rse Events
An AEis any untoward medical occurrence in a clinical investigation subject administered a 
pharmaceutical prod uct and that does not necessarily have a causal relationship with this 
treatment. An AE can therefore be a
ny unfavorable and unintended sign, (including an abnormal 
laboratory finding), sym ptom, or disease temporally associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product (ICH 
Guidance E2 A 1995).
All AEs are coll ected from the time the informed consent is signed until the defined foll ow-up 
period stated in Section 7.1.3 . This include s events occurring during the screening phase of the 
study, regardless of whether or not investigational pro duct is administered. Wh ere possible, a 
diagnosis rather than a list of sy mptoms should be recorded. If a diagnosis has not been made, 
then each symptom should be listed individually. All AEs should be captured on the appropriate 
AE pages in the CRF and in source documents. In addition to untoward AEs, unexpected 
benefits outside the investigational product indication should also be captured on the AE CRF.
All AEs must be followed to closure (the subject’s health has returned to his/her baseline status 
or all variables have returned to normal), regardless of whether the subject is still participating in 
thestudy. Closure indicates that an outcome is reached, stabilization achieved (the investigator 
does not expect any further improvement or worsening of the event), or the event is otherwise 
explained. When appropriate, medical tests and examinations are performed so that resolution of 
event(s) can be documented.
8.1.1 Severity Categorization
The severit y of AEs must be recorded during the course of the event inclu ding the start and stop 
dates for each change in severity. An event that changes in severity should be captured as a new 
event. Worsening of pre -treatment events, after initiation of investigational product, must be 
recorded as new AEs (for example, if a subject experiences mild intermittent dy spepsia prior to 
dosing of investigational product, but the dy spepsia becomes severe and more frequent after first 
dose of investigational product has been administered, a new AE of severe dy spepsia [with the 
appropri ate date of onset] is recorded on the appropriate CRF).
The medical assessment of severit y is determined by using the following definitions:
Mild: A
type of AE that is usually transient andmay require only minimal 
treatment or therapeutic intervention. Th e event does not general lyinterfere 
with usual activities of daily living.
Moderate: A type of AEthatisusuall yalleviated with specific therap eutic
intervention. The event interferes withusual activities ofdailyliving,
causing discomfort but poses no significant or permanent risk of harm to the 
research subject.
Severe: A type of AE that interrupts usual activities of daily living, or 
significant ly affects clinical status, or may require intensive therapeutic 
intervention.
For non-commercial use only
Shire CONFIDENTIAL Page 70
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
8.1.2 Relationship Categorization
A physician/investigator must make the assessment of relationship to investigational product for 
each AE. The investigator should decide whether, in his or her medical judgment, there is a 
reasonable possibility that the event ma yhave been caused by the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related”. Otherwise, if there is any valid reason, even if undetermined or untested, for suspecting 
a possi ble cause- and-effect relationship between the investigational product and the occurrence 
of the AE, then the AE should be considered “related”. The causality assessment must be 
documented in the source document.
The following additional guidance may be hel pful:
Term Relationship Definition
RelatedThe temporal relationship between the event and the administration of the 
investigational product is compelling and/or follows a known or suspected response 
pattern to that product, and the event cannot be explai ned by the subject’s medical 
condition, other therapies, or accident.
Not RelatedThe event can be readily explained by other factors such as the subject’s underlying 
medical condition, concomitant therapy, or accident and no plausible temporal or 
biologi c relationship exists between the investigational product and the event.
8.1.3 Outcome Categorization
The outcome of AEs must be recorded during the course of the stu dy on the CRF. Outcomes are 
as follows:
Fatal
Not Recovered/Not Resolved
Recovered/Resolved
Recovered/Resolved With Sequelae
Recovering/Resolving
Unknown
8.1.4 Clinical Laboratory and Other Safety Evaluations
A change in the value of a clinical laborato ry, vital sign, or ECG assessment can represent an 
AEif the change is clinically  relevant or if, dur ing treatment with the investigational product, a 
shift of a parameter is observed from a normal value to an abnormal value, or a furt her 
worsening of an alre a
dy abnormal value. When evaluating such changes, the extent of deviation 
from the reference range , the duration until return to the reference r ange, either while continuing 
treatment or after the end of treatment with the investigational product, and the range of variation 
of the respective parameter within its reference range, must be taken into cons ideration.
For non-commercial use only
Shire CONFIDENTIAL Page 71
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
If, at the end of the treatment phase , there are abnormal clinical laborato ry, vital sign, or ECG 
values which were not present at the pretreatment value observed closest to the start of study  
treatment, further investigations should be performe d until the values return to within the 
refere nce range or until a plausible explanation (eg, concomitant disease) is found for the 
abnormal values.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whethe r a change in a clinical laboratory , vital sign, or ECG parameter is clinica lly 
significant and therefore represents an AE.
8.1.5 Pregnancy
All pregnancies are to be reported from the time informed consent is signed until last visit (or 
last contact with the sub ject) stated in Section 7.1.3 .
Any report of pregnancy  for any  female study  participant must be reported within 24 hours to the 
Shire Global Safet y Department using the Shire Investigational and Marketed Products 
Pregnancy  Report Form. A copy  of the Shire Investigational and Marketed Products Pregnancy 
Report Form (and an y applicable follow -up reports) must also be sent to the CRO/Shire medical 
monitor using the details specified in the emergency  contact information section of the protocol. 
The pregnant fem ale study  participant must be withdrawn from the study .
Everyeffort should be made to gather information regarding the pregnancy outcome and 
condition of the infant. It is the responsibility of the investigator to obtain this information within 
30 calenda r days after the initial notification and appr oximately 1 year post partum.
Pregnancy complications such as spontaneous abortion/misc arriage or congenital abnormality
areconsidered SAEs and must be reported using the Shire Clinical Study Serious Adverse Event 
and Non -serious AEs Required by the Protocol Form. Note: An elective abortion is not 
considered an SAE.
In addition to the above, if the investigator determines that the pregnancy meets serious 
criteria, it must be reported as an SAE using the Shire C linical Study Serious Adverse Event and 
Non-serious AEs Required by the Protocol Form as well as the Shire Investigational and 
Marketed Products Pregnancy Report Form. The test date of the first positive serum/urine -hCG 
test or ultrasound result will determine the pregnancy onset date.
8.1.6 Abuse, Misuse, Overdose, and Medication Error
Abuse, misuse, overdose, or medication error (as defined below) must be reported to the sponsor 
according to the SAE reporting procedure whether or not they result in an AE/SAE as described 
in Section 8.2. Note: The 24 -hour reporting requirement for SAEs does not apply to reports of 
abuse, misuse, overdose, or medication errors unless these result in an SAE.
For non-commercial use only
Shire CONFIDENTIAL Page 72
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
The categories below are not mutually exclusive; the event can meet more than 1 catego ry.
Abuse –Persistent or sporadic intentional intake of investigational product when used 
for a non -medical purpose (eg,toalter one’s state ofconsciousness or get high) ina
manner that may be detrimental to the individual and/or society
Misuse – Intentional useofinvestigational product other than asdirected or
indicated at an y dose(Note: thisincludes asituation wher ethe investigational
product isnotused as directed at the dose prescribed bythe protocol)
Overdose – Intentional or unintentional intake of a dose of investigatio nal product 
higher than the protocol- prescribed dose
Medication Error –An error made in prescribing, dispensing, administration, and/or 
use of an investigational product. For studies , medication errors are reportable to the 
sponsor only as defined below.
Cases of subjects missing doses of the investigational product are not considered reportable as 
medication errors.
Medication errors should be collected/reported for all products unde r investigation.
Theadministration and/or use of the unassigned treatment is/are always reportable as a 
medication error.
The administration and/or use of an expired investigational product should be considered as a 
reportable medication error. Violation of storage or refrigera tion requirements for the 
investigational product is considered a reportable medication error and as such must be reported 
to the sponsor.
8.2 Serious Adverse Event Procedures
8.2.1 Reference Safety Information
The reference for saf ety informa tion for this study is the Investigator’s Brochure which the 
sponsor has provided under separate cover to all investigators. However, this is the first clinical 
experience with SHP681 in humans. While major AEs are not anticipated, the investigator 
should proceed with caution. Equipment, supplies, and prope rly skilled medical personnel should 
be immediately available for emergency use in the event of an unexpected reaction. Subjects 
must be carefully selected and monitored clos ely.
8.2.2 Reporting Procedures
All initial and follow -up SAE reports must be reported by  the investigator to the Shire Global 
Safety  Department and the CRO/Shire medical monitor within 24 hours of the first awareness of 
the event. Note: The 24 -hour reporting requirement for SAEs does not ap ply to reports of abuse, 
misuse, overdose, or medication errors (see Section 8.1.6) unless they  result in an SAE.
For non-commercial use only
Shire CONFIDENTIAL Page 73
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
The investigator must complete, sign, and date the Shire Clinical Study Serious Adverse Event 
and Non -serious AEs Required by the Protocol Form and verify theaccur acyof the information 
recorded on the form with the corresponding source documents (Note: Source documents are not 
to be sent unless requested) and fax or e-mail the form to the Shire Global Pharmacovigilance 
and Risk Management D epartment.
A copy of theShire Clinical StudySerious Adverse Event and Non- serious AEs Required bythe 
Protocol Form (and a nyapplicable follow -up reports) must also be sent to the CRO/Shire 
medical monitor using the details specified in the emergency contact information section of the 
protocol.
8.2.3 Serious Adverse Event Definition
A serious adverse event (SAE) is any untoward medical occurrence (whether considered to be 
related to investigational product or not) that at any dose:
Results in death
Is life-threatening. Note: The t erm “li fe-threatening” in the definition of “serious” re fers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event which hypothetically might have caused death if it was more s evere.
Requires inpati ent hospitalization or prolongation of existing hospitaliz ation.
Note: Hospitalizations that are the result of elective or previous lyscheduled surgery for
pre-existing conditions and have not worsened after initiation of treatment should not be 
classified as SAEs. For example, an admission for a previously scheduled ventral hernia 
repair would not be classified as an SAE; however, complication(s) resulting from a 
hospitalization for an elective or previous ly scheduled surgery that mee t(s) serious criteria 
must be reported as SAE(s).
Results in persistent or significant disability /incapacity
Is a congenital abnormali ty/birth defect
Is an important medical event. Note: Important medical events that may not result in death, 
be life-threatening, or require hospitalization may be considered an SAE when, based upon 
appropriate medical judgment, they may jeopardize the subject and may require medical or 
surgical intervention to prevent 1 of the outcomes listed in this definition. Example s of such 
medical events include allergic bronchospasm requiring intensive treatment in an emergency
room or at home; blood d yscrasias or convulsions that do not result in inpatient 
hospitalization; or the development of drug dependency or drug abuse.
8.2.4 Serious Adverse Event Collection Time Frame
All SAEs (regardless of relationship to study ) are collected from the time the subject signs the 
informed consent until the defined follow- up period stated in Section 7.1.3 and must be reported 
to the Shire Global Pharmacovigilance and Risk Management Department and the CRO/Shire 
medical monitor within 24 hours of the first awareness of the event.
For non-commercial use only
Shire CONFIDENTIAL Page 74
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
In addition, any SAE(s) considered “related” to the investigational product and discovered by  the 
investigator at an y inte rval after the study  has completed must be reported to the Shire Global 
Pharmacovigilance and Risk Management Department within 24 hours of the first awareness of 
the event.
8.2.5 Serious Adverse Event Onset and Resolution Dates
The onset date of the SAE is defined as the date the event meets serious criteria. The resolution 
date is the date the event no longer meets serious criteria, the date the s ymptoms resolve, or the 
event is considered chronic. I n the case of hospitalizations, the hospital admission and dis charge 
dates are considered the onset and resolution dates, respectivel y.
In addition, any  signs or sy mptoms experienced by  the subject after signing the informed consent 
form, or leading up to the onset date of the SAE, or following the resolution date of the SAE, 
must be recorded as an AE, if appropriate.
8.2.6 Fatal Outcome
Any SAE that results in the subject’s death (ie, the SAE was noted as the primary  cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution dat e. For 
all other events ongoing at the time of death that did not contribute to the subject’s death, the 
outcome should be considered not resolved, without a resolution date recorded.
For an y SAE that results in the subject’s death or any ongoing events at the time of death, unless 
another investigational product action was previously  taken (eg, drug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subjec t never received investigational product). The 
investigational product action of withdrawn should not be selected solel y as a result of the 
subject’s death.
8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site 
Reporting
The sponsor is responsible for noti fying the relevant regulatory authorities of related, unexpected 
SAEs.
In addition the sponsor is responsible for notify ing active sites of all related, unexpected SAEs 
occurring during all interventional studies across the SHP681 program.
The investigator is responsible for notify ing the local IRB, local EC, or the relevant local 
regulatory authori ty of all SAEs that occur at his or her site as required.
For non-commercial use only
Shire CONFIDENTIAL Page 75
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
9.DATA MANAGEMENT AND STATISTICAL METHODS
9.1 Data Collection
The investigators’ authorized site personnel must enter the information required by the protocol 
on the CRF. A study monitor will visit each site in accordance with the monitoring plan and 
review the CRF data against the source data for co mpleteness and accurac y. Discrepancies 
between source data and data entered on the CRF will be addressed by qualified site personnel. 
When a data discrepancy warrants correction, the correction will be made by authorized site 
personnel. Data collection proc edures will be discussed with the site at the site initiation visit 
and/or at the investigator’s meeting. Once a subject is randomized, it is expected that site 
personnel will complete the CRF entry
within a reasonable window of the subject’s visit.
9.2 Clinical Data Management
Data are to be entered into a clinical database as specified in the CRO data management plan. 
Quality  control and data validation procedures are applied to ensure the validity  and accuracy  of 
the clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all co rrections are documented in an auditable manner.
9.3 Data Handling Considerations
Data that may  potentiall y unblind the treatment assignment (ie, investigational product blood 
concentrations, antibodies to SHP681,  
, treatment allocation, and investigational product preparation/accountability  data, 
will be handled with special care during the data cleaning and review process. These data will be 
handled in such a way  that, prior to unblinding, any  data that may  unblind study  team personnel 
will be presented as blinded information or otherwise will not be made available. If applicable, 
unblinded data may  be made available to quality  assurance representatives for the purposes of 
conducting independent drug audits.
9.4 Statistical Analysis Process
The study  will be anal yzed by  the sponsor or its agent.
The statistical anal ysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the PK and safety  data, as well as describe the approaches to be taken for 
summarizing other study  information such as subject disposition, demographics and baseline 
characteristics, investigational product exposure, and prior and concomitant medications. The 
SAP will also include a description of how m issing, unused and spurious data will be addressed.
For non-commercial use only
Shire CONFIDENTIAL Page 76
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Descriptive anal ysis will be performed to evaluate PK endpoints and safet y endpoints. All 
analyses/summaries will be based on observed data, with missing data handling rules specified in 
Section 9.8.1 or the SAP.
Continuous endpoints will be summarized with the number of subj
ects (n), mean, standard 
deviation (SD), median, minimum and maximum value. As appropriate, raw (actual) values, 
changes from baseline, and percent changes from baseline will be summar ized at each scheduled 
timepoint. Baseline is defined as the last non -missing value observed prior to dosing with 
SHP681 or placebo. Additional summary  statistics will be provided for PK endpoints and are 
indicated in Section 9.8.1.
Categorical endpoints w ill be summarized, display ing counts and percentages. Summaries will 
include, where applicable: number and percentage of subjects with an outcome measure and shift 
tables (categorical change from baseline). Summaries will be presented b y dose cohort and fo
r 
the placebo group, and, if appropriate, b y scheduled timepoint.
All data, including derived data, will be presented in subject data listings.
To preserve the integrit y of the statistical anal ysis and study  conclusions, the SAP will be 
finalized prior to database lock.
The pharmacokinetic analy sis will be conducted using Phoenix WinNonlin version 6.2 or higher 
(Pharsight Corporation, Mountain View, California, USA). The statistical anal yses will be 
performed using SAS®(SAS I nstitute, Cary , NC 27513).
9.5 Plan ned Interim Analysis, Adaptive Design, and Data Monitoring Committee
To support an initiation of the MAD phase and confirm the dosing interval, an interim data 
analysis will be required. Blinded plasma data obtained after dosing in Cohort 1, Cohort 2, and 
part of Cohort 3 in the SAD portion will be evaluated and justified for this purpose.
An interim anal ysis will be performed after the last patient from the 3rd MAD cohort has 
completed the Day  39 visit, to determine the dose level of the 6th MAD cohort, an d to assess an y 
safet y, tolerabilit y, or pharmacokinetic questions based on the safety review. The data for this 
analysis will be source data verified and cleaned according to the Interim Snapshot Plan. This 
analysis will unblind all completed SAD cohorts and the first 3 MAD cohorts for the Sponsor 
and external statistical groups. MAD cohorts 4, 5 and 6 will not be unblinded to an y parties due 
to this interim analy sis.
No adaptive design or data monitoring c ommittee (DMC) is planned.
For non-commercial use only
Shire CONFIDENTIAL Page 77
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
9.6 Sample Size Calculat ion and Power Considerations
SAD (Par t 1)
It is planned that dose escalation will proceed for up to 5 dose levels. Each cohort will 
include 5 subjects treated with SHP681 and 1 subject treated with placebo for a planned total of 
30 subjects. However, if dose levels are r epeated, modified, or not conducted or if additional 
dose levels are studied, the total number of subjects may change. The number of subjects is 
expected to provide reasonable information on initial testing of SHP681 for saf etyand PK while 
exposing as few subjects as possible to investigational drug materials. The number of subjects in 
thisstudy is not based on statistical hypothesis testing and power considerations as this is the first 
in human study . The statistical ana lyses are primaril y descriptive, and no hypothesis testing is 
specified for this portion.
MAD (Part 2)
It is planned that the MAD portion of the study will include 6 cohorts. Each cohort will 
include 10 subjects treated with SHP681 and 2 subjects treated with placebo for a planned total 
of 72 subjects. The number of subjects is expected to provide reasonable information on initial 
testing of SHP681 for safety
 and PK while exposing as few subjects as possible to 
investigational drug materials. The number of subjects in this st udy is not based on statistical 
power considerations as this is the first time in human study . The statistical anal yses are 
primarily  descriptive, and no hy pothesis testing is specified in the study .
9.7 Study Population
Subject populations are separately  defined to analy ze the data in the SAD portion and the MAD 
portion of the study:
SAD
The safet y analysis set includes subjects who have received at least 1 dose of SHP681 
or placebo in the SAD portion.
The PK anal ysis set consists of subjects who have received at least 1 dose of SHP681 
and have at least 1 evaluable post-dose PK concentration value in the SAD portion.
MAD
The safet y analysis set includes subjects who have received at least 1 dose of 
SHP681or placebo in the MAD portion.
The PK anal ysis set consists of subjects who have received at least 1 dose of SHP681 and have at 
least 1 evaluable post -dose PK concentration value in the MAD portion.
For non-commercial use only
Shire CONFIDENTIAL Page 78
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
9.8 Pharmacokinetic Analyses
9.8.1 Pharmacokinetic Analysis
The PK ana lysis will be based on the PK analy sisset.
Pharmacoki netic parameters will be calculated from plasma SHP681 concentration -time data 
using non- compartmental methods and all c alculations will be b ased on actual sampling times. 
Pharmacokinetic parameters will include, but not be limited to, the following:
SAD 
Cmax Maximum concentration occurring at t max 
tlast Time of the last measurable concentration
tmax Time of maximum observed concentration sampled during a dosing interval
AUC 0-lastArea under the curve from the time of dosing to the last measurable concentration
AUC 0-∞ Area under the curve extrapolated to infinity
 t1/2 Terminal half -life
  z First order rate constant associated with the terminal (log- linear) portion of the 
curve
CL/F Apparent total bod y clearance for extravascular administration divided by the 
fraction of dose absorbed calculated as dose divided by  AUC0 -∞. 
Vz/F Apparent volume of distribution following extravascular administration divided 
by the fraction of dose absorbed calculated as CL/F divided by  z. 
MAD 
Post first dose
AUC 0
-24Area under the curve from the time of dosing to the 24 hours post first dose
Cmax,24 Maximum concentration occurring during 24 hours after first dose 
tmax,24 Time of maximum observed concentration during 24 hours after first dose 
Between the first dose and last dose
Ctrough Observed concentration at the end of each dosing interval 
(immediately  before next dose for the first 5 cohorts and immediately  before 
2ndand 3rddose of the 6thMAD cohort)
Post last dose
Cmax Maximum concentration during the dosing inte rval occurring at t max
For non-commercial use only
Shire CONFIDENTIAL Page 79
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Tlast Time of the last measurable concentration
tmax Time of maximum observed concentration during the dosing interval 
AUC tau Area under the curve for the defined interval between doses (onl y calculated if 
interpretable)
AUC 0-lastArea under the curve from the time of dosing to the last measurable concentration 
post last dose 
AUC 0-∞ Area under the curve (post last dose) extrapolated to infinity , calculated using the 
observed value of the last non- zero concentrations (only  calculated if 
interpretable)
t1/2 Terminal half -life 
  z First order rate constant associated with the terminal (log- linear) portion of the 
curve 
CL/F Apparent total bod y clearance following extravascular administration divided by 
the fraction of dose absor bed calculated as dose divided by  AUC tau
Vz/F Apparent volume of distribution following extravascular administration divided 
by the fraction of dose absorbed calculated as CL/F divided by  z
9.8.1.1 Statistical Analysis of Pharmacokinetic Parameters
The pharmacokinetic ana lysis will be conducted by the pharmacokinetics CRO.
The applicable an alysis conventions will be detailed in the statistical an alysis plan, including the 
minimum number of quantifiable postdose concentrations to be used to derive AUC, ha ndling 
rules of concentration values below the assay quantitation limit (BLQ), handling of potential 
anomalous predose concentration values, etc. Subjects randomized to SHP681 but excluded from 
the PK analy sis set will be listed by subject and reason(s) le ading to exclusion.
SAD
The PK analy sis will be based on the PK ana lysis set for the SAD portion.
Individual subject’s raw concentrations of SHP681and actual sampling time will be listed by  
nomin al sampling timepoint. Individual subject’s PK parameters wil l be listed by dose cohort, 
along with the number of timepoints of the terminal log-linear phase used to estimate the 
terminal rate constant and percentage of extrapolated AUC.
Raw concentrations for each nominal sampling timepoint and PK parameters except tmaxand t last 
will be summarized by dose cohort with descriptive statistics such as number of subjects, 
geometric mean, median, arithmetic mean, standard, deviation, coefficient of variation, and 
geometric coefficient of variation, minimum and maximum. The other parameters, tmaxand t last, 
will be summa rized by median, minimum and maximum grouped by dose cohort.
For non-commercial use only
Shire CONFIDENTIAL Page 80
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Individual subject’s concentration -time curves will be presented in linear/linear and log/linear 
scale using lattice plots, with one panel for each subject grouped b y dose cohort. Figures 
showing the mean (with ±SD as error bar) as well as the median (with 25th to 75th quantiles as 
error bar) concentration time profiles will be presented in linear/linear and log/linear scale using 
lattice plots, with one panel for each dose cohort. Mean and median concentration time profiles 
for all dose cohorts will be also visualized in one plot.
MAD
The PK anal ysis will be based on the PK analy sis set for the MAD portion.
Individual raw concentration data and a ctual sampling time will be listed by  nominal sampling 
timepoint. Individual subject’s PK parameters derived post the first dose and repeat doses 
(ie,after the last dose) will be listed by dose cohort, along with the number of timepoints of the 
terminal log-linear phase used to estimate the terminal rate constant and percentage of 
extrapolated AUC if applicable.
Raw concentrations for each nominal sampling timepoint and PK parameters post the fi r
st dose 
and repeat doses, except tmax, 24, tmaxand t last, will be summarized by dose cohort with descriptive 
statistics such as number of subjects, geometric mean, median, arithmetic mean, standard, 
deviation, coefficient of variation, and geometric coeffi cient of variation, minimum and 
maximum where t max, 24, tmaxand t lastwill be summarized by median, minimum a ndmaximum 
grouped by dosecohort.
Individual subject’s concentrati on-time profile up to 24 hours after the first dose will be 
visualized with cor respondin
gly superimposed concentrati on-time profile up to 24 hours 
following the 5th dose in linear/linear and log/linear scale using lattice plots, with one panel for 
each subject grouped b
ydose cohort.
Individual concentration- time curves following after the last dose will be presented in 
linear/linear and log/linear scale using lattice plots, with one panel for each subject grouped by
dose cohort. Mean (with ±SD as error bar) as well as the median (with 25th to 75th quantiles as 
error bar) concentration time profiles will be presented in linear/ linear and l og/linear scale using 
lattice plots, with one panel for each dose cohort. Mean and median concentration time profiles 
for all dose cohorts will be superimposed in one plot.
9.9 Safety Analyses
For each portion, statistical analysis of safety data will be based on the safety analysis data set for 
the portion. Descriptive an alysis, as described in Section 9.4will be performed to evaluate all 
safetyendpoints.
Safety datawill be listed bysubject and summarized for each dose cohort of SHP681 and a 
pooled placebo group of all subjects who were administered placebo, using descriptive statistics. 
Continuous variables will be summarized by sample size, mean, standard deviation, median, 
minimum and maximum. Categorical variables will be summarized by number of subject s and 
the percent of subjects in each catego ry.
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 82
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
10.SPONSOR’S AND INVE STIGATOR’S RESPONSIB ILITIES
This studyis conducted in accordance with current applicable regulations, ICH, and local ethical 
and legal requirements.
The name and address of each third-party vendor (eg, CRO) used in this study will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1 Sponsor’s Responsibilities
10.1.1 Good Clinical Practice Compliance
The study sponsor and any thirdpartyto whom aspects of the study management or monitoring 
have been d elegated will undertake their assigned roles for this study in compliance with all 
applicable industry regulations, ICH GCP Guideline E6 (1996), EU Directive 2001/20/EC, as 
well as all applicable national and local laws and regulation s.
Visits to sites are conducted by representatives of the study sponsor and/or the compan y 
organizing/managing the research on behalf of the sponsor to inspect study data, subjects’ 
medical records, and CRFs in accordance with current GCP and the respective local and 
inter/nat ional government regulations and guidelines. Records and data may additionally be 
reviewe d by auditors or by regulato r yauthorities.
The sponsor ensures that local regulatory authority requirements are met before the start of the 
study. The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of any regulatory authorit yapprovals required prior to release of 
investigational product for shipment to the site.
10.1.2 Public Posting of Study Information
The sponsor is responsible for posting appropriate study  information on applicable websites. 
Information included in clinical study  registries may  include participating investigators’ names 
and contact information.
10.1.3 Indemnity/Liability and Insurance
The sponsor ensures that suitable clinical study  insurance coverage is in place prior to the start of 
the study . An insurance certificate is supplied to the investigator as necessary .
10.1.4 Submission of Summary of Clinical Study Report to Competent Authorities of 
Member S tates Concerned and Ethics Committees
The sponsor will provide a summary oftheclinical study report to the competent authority of the 
member state(s) concerned as required by regulatory requirement(s) and to comply with the 
Communi tyguideline on GCP. This requirement w ill be fulfilled within 6 months of the end of 
thestudy completion date for pediatric studies and within 1 y ear for non- pediatric studies as per 
guidance.
For non-commercial use only
Shire CONFIDENTIAL Page 83
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
10.1.5 Study Suspension, Termination, and Completion
The sponsor may suspend or terminate the study, or pa rt of the stud y, at any time for any reason. 
If the stud y is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and IRBs/ECs are notified as appropriate. Additionally , the discontinuation of a 
regist ered clinical st udy which has been posted to a designated public website will be updated 
accordin g
ly.
10.2 Investigator’s Responsibilities
10.2.1 Good Clinical Practice Compliance
The investigator must undertake to perform the study in accordance with ICH GCP Guideline E6 
(1996), and applicable regulatory requirements and guidelines.
It is the investigator’s responsibility to ensure that adequate time and appropriately trained 
resources are available at the site prior to commitment to participate in this study. The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately qualified persons to whom the investigator 
has delegat edsignificant study-related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any licenses and certifications necessary to demonstrate such 
qualification. Curriculum vitae for investigators and sub-inves tigators are provided to thestudy  
sponsor (or designee) before starting the study.
If a potential research subject has a primary care physician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the stud
y.
Agreement with the final clinical study report is documented by the signed and dated signature of 
the principal investigator, in compliance with Directive 2001/83/EC as amended byDirective 
2003/63/EC andICH Guidance E3 (1995 ).
10.2.2 Protocol Adherence and Inve stigator Agreement
The investigator and a n
y co- investigators must adhere to the protocol as detailed in this 
document. The investigator is responsible for enrolling only those subjects who have met 
protocol eligibility criteria. Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply with thestudy protocol.
If the investigator suspends or terminates the study  at their site, the investigator will promptly  
inform the sp onsor and the I RB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational product, containers, and other study materials to 
the sponsor. Upon study  completion, the investigator will provide the sponsor , IRB/EC, and 
regulatory  agency  with final reports and summaries as required by  (inter)national regulations.
For non-commercial use only
Shire CONFIDENTIAL Page 84
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Communication with local I RBs/ECs, to ensure accurate and timel y information is provided at 
all phases during the study , may  be done by  the sponsor , applicable CRO, investigator, or, for 
multicenter studies, the coordinating principal investigator, according to national provisions, and 
will be documented in the investigator agreement.
10.2.3 Documentation and Retention of Records
10.2.3.1 Case Report Forms
Case repo rt forms are supplied by thesponsor and should be handled in accordance with 
instructions from the sponsor.
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded onto CRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed by the investigator or designee as stated in the site delegation log.
All data will have separate source documentation ; no data will be recorded directly onto the 
CRF.
All data sent to the sponsor must be endorsed b
y the investigator.
The CRA/study monitor will verify the contents against the source data per the monitoring plan. 
If the data are unclear or contradicto ry, queries are sent for corrections or verification of data.
10.2.3.2 Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study will include, but are not limited to: 
subject’s medical file , original clinic al laboratory reports, and h istolo gyandpathology reports. 
All key data must be recorded in the subject’s medical records.
The investigator must permit authorized representatives of the sponsor; the respective national, 
local, or foreign regulatory authorities; the IRB/EC; and auditors to inspect facilities and to have 
direct access to original source records relevant to this stu dy, regardless of media.
The CRA/study monitor (and auditors, IRB/EC, or regulatory inspectors) maycheck the CRF 
entries against the source documents. The consent form includes a statem ent bywhich the 
subject agrees to the monitor/auditor from the sponsor or its representatives, national or local 
regulatory authorities, or IRB/EC, having access to sour ce data (eg, subject’s medical file, 
appointment books, original laboratory reports, X -rays, etc.).
These records must be made available within reasonable times for inspection and duplication, if 
required, by a proper lyauthorized representative of any regulator yagen cy(eg, the US FDA, 
EMA, UK Medicines and Hea lthcare products Regulatory Agen cy) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may not be 
destr oyed without writ ten permission from the sponso r.
For non-commercial use only
Shire CONFIDENTIAL Page 85
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
10.2.3.3 Audit/Inspection
To ensure compliance with relevant regulati ons, data generated b ythisstudy must be available 
for inspection upon request by representatives of, for example, the US FDA (as well as other US 
national and local regulatory authorities), the EMA, the Medicines and Healthcare products 
Regulatory Agen cy,other regulator yauthorities, the sponsor or its representatives, and the 
IRB/EC for each site.
10.2.3.4
Financial Disclosure
The investigator is required to disclose an y financial arrangement during the study  and for 1 y ear 
after, whereb y the outcome of the study  could be influenced by  the value of the compensation for 
conducting the study , or other pay ments the investigator received from the sponsor. The 
following information is collected: an y significa nt pay ments from the sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in the form of equipment, retainer for 
ongoing consultation or honoraria; an y proprietary interest in investigational product; an y 
significant equity  intere st in the sponsor or subsidiaries as defined in 21 CFR 54 2(b) (1998).
10.3 Ethical Considerations
10.3.1 Informed Consent
It is the responsibility  of the investigator to obtain written informed consent from all study  
subjects prior to an y study -related procedures inc luding screening assessments. All consent 
documentation must be in accordance with applicable regulations and GCP. Each subject or the 
subject’s legall y authorized representative, as applicable, is requested to sign and date the subject 
informed consent fo rm or a certified translation if applicable, after the subject has received and 
read (or been read) the written subject information and received an explanation of what the study 
involves, including but not limited to: the objectives, potential benefits and risk, inconveniences, 
and the subject’s rights and responsibilities. A copy of the informed consent documentation (ie, a 
complete set of subject information sheets and fully executed signature pages) must be given to 
the subject or the subject’s legally  authorized representative, as applicable. This document may  
require translation into the local language. Signed consent forms must remain in each subject’s 
study  file and must be available for verification at any  time.
The principal investigator provides the sponsor with a cop y of the consent form that was 
reviewed b y the IRB/EC and received their favorable opinion/approval. A copy  of the IRB/EC’s 
written favorable opinion/approval of these documents must be provided to the sponsor prior to 
the start of the study  unless it is agreed to and documented (abiding by  regulatory  guidelines and 
national provisions) prior to study  start that another part y (ie, sponsor or coordinating principal 
investigator) is responsible for this action. Additionally , if the IRB/EC requires modification of 
the sample subject information and consent document provided by  the sponsor, the 
documentation supporting this requirement must be provided to the sponsor.
For non-commercial use only
Shire CONFIDENTIAL Page 86
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
10.3.2 Institutional Review Board or Ethics Committee
For sites outside the EU, it is the responsibility  of the investigator to submit this protocol, the 
informed consent document (approved b y the sponsor or their designee), relevant supporting 
information and all ty pes of subject recruitment information to the I RB/EC for review, and al l 
must be approved prior to site initiation.
The applicant for an EC opinion can be the sponsor or investigator for sites within the EU; for 
multicenter studies, the applicant can be the coordinating principal investigator or sponsor, 
according to national provisions.
Responsibility  for coordinating with IRBs/ECs is defined in the clinical trial agreement. Prior to 
implementing changes in the study , the sponsor and the I RB/EC must approve any  revisions of 
all informed consent documents and amendments to the protocol unless there is a subject safet y 
issue.
Investigational product supplies will not be released until the sponsor has received written 
IRB/EC approval of and copies of revised documents.
For sites outside the EU, the investigator is responsible for keeping the IRB/EC apprised of the 
progress of the stud y and of an y changes made to the protocol, but in an y case at least once a 
year; for sites within the EU, this can be done by  the sponsor or investigator, or, for multicenter 
studies, it can be done b y the coordinating principal investigator, according to national 
provisions. The investigator must also keep the local IRB/EC informed of any  serious and 
significant AEs.
10.4 Privacy and Confidentiality
All U S-based sites and laboratories or entities providing support for this study , must, where 
applicable, comp ly with HIP AA of 1996. A site that is not a covered entity asdefin ed by HI PAA 
must provide documentation of this fact to the sponsor.
The confidentiali ty of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, and guid elines.
After subjects have consented to take part in the study , the sponsor and/or its representatives’ 
reviews their medical records and data collected during the st udy. These re cords and data ma y, in 
addition, be reviewed byothers including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may develop, register, or 
market SHP681; national or local regulatory authorities; and the IRB(s)/EC (s) which gave 
approval for the stu dy to proceed. The sponsor and/or its representatives accessing the records 
and data will take all reasonable precautions in accordance with applicable laws, regulations, and 
guidelines to mai ntain the confidentialit y of subjects’ identities.
For non-commercial use only
Shire CONFIDENTIAL Page 87
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Subjects are assigned a unique identify ing number; however, their initials and date of birth may  
also be collected and used to assist the sponsor to verify  the accuracy  of the data (eg, to confirm 
that lab oratory  results have been assigned to the correct subject).
The results of studies –containing subjects’ unique identify ing number, relevant medical 
records, and possibly  initials and dates of birth –will be recorded. They  may  be transferred to, 
and used in, other countries which may  not afford the same level of protection that applies within 
the countries where this study  is conducted. The purpose of an y such transfer would include: to 
support regulatory  submissions, to conduct new data anal yses to publi sh or present the study  
results, or to answer questions asked by  regulatory or health authorities.
10.5 Study Results/Publication Policy
Shire will endeavor to publish the results of all qualify ing, applicable, and covered studies 
according to external guidelines in a timely manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additional ly, Shire adheres to external guidelines 
(eg,Good Publication Practices 2) when forming a publication steering committee. The purpose 
of the publication steering committee is to act as a non- commercial bo dythat advises or decides 
on dissemination of scientific study data in accordance with the scope of this policy.
All publications relating to Shire products or projects must undergo appropriate technical and 
intellectual prope rty review, with Shire agreement to publish prior to release of information. The 
review is aimed at protecting the sponsor’s proprietary information existing either at the 
commencement of the study or gen erated d uring the stu dy. To the extent permitted by the 
publisher and co pyrightlaw, the principal investigator will own (or share with other authors) the 
copyright on his/her publications. To the extent that the principal investigator has such sole, 
joint or shar ed rights, the principal investigator grants the sponsor a perpetual, ir revocable, 
royalty- free license to make and distribute copies of such publications.
The term “publication” refers to any public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplements, 
letters to the editor, invited lectures, opinion pieces, book chapters, electronic postings on 
medical/scientific websites, or other disclosure of the study results, in printed, electronic, oral or 
other form.
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study  results, and any  background information provided by  the sponsor that is necessary  to 
include in an ypublication of study  results, or necessary  for other scholars to verify  such study  
results. Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
confidential information shall be submitted for publication without the sponsor’s pri or written 
agreement to publish, and shall be given to the sponsor for review at least 60 days prior to 
submission for publication. If requested in writing by  Shire, the institution and principal 
investigator shall withhold submission of such publication f or up to an additional 60 day s to 
allow for filing of a patent application.
For non-commercial use only
Shire CONFIDENTIAL Page 88
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
If the stud y is part of a multicenter study, the first publication of the study results shall be made 
by the sponsor in conjunction with the sponsor’s presentation of a joint, mult icenter publication 
of the compiled and analy zed study  results. If such a multicenter publication is not submitted to a 
journal for publication by  the sponsor within an 18-month period after conclusion, abandonment, 
or termination of the study  at all sites , or after the sponsor confirms there shall be no multicenter 
study  publication of the study  results, an investigator may individuall y publish the study results 
from the specific site in accordance with this section. The investigator must, however, 
acknowl edge in the publication the limitations of the single -site data being presented.
Unless otherwise required by  the journal in which the publication appears, or the forum in which 
it is made, authorship will comply  with the International Committee of Medical Journal Editors 
(ICMJE) current standards. Participation as an investigator does not confer any  rights to 
authorship of publications.
For non-commercial use only
Shire CONFIDENTIAL Page 89
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
11.REFERENCES
Amiot, A., Messing, B., Corcos, O., Panis, Y.and Joly , F. 2013. Determinants of home parente ral 
nutrition dependence and survival of 268 patients with non-malignant short bowel 
syndrome. Clinical Nutrition, 32, 368-374.
Bakker, H., Bozzetti, F., Staun, M., Leon -Sanz, M., Hebuterne, X., Pertkiewicz, M., Shaffer, 
J.and Thul, P. 1999. Home parentera l nutrition in adults: a european multicentre survey  in 
1997. ESPEN -Home Artificial Nutrition Working Group. Clin Nutr, 18, 135 -40.
Dudrick, S. J., Latifi, R.and Fosnocht, D. E. 1991. Management of the short- bowel syndrome. 
Surg Clin North Am, 71, 625 -43.
Goulet, O., Baglin- Gobet, S., Talbotec, C., Fourcade, L., Colomb, V., Sauvat, F., Jais, J.-P., 
Michel, J.-L., Jan, D.and Ricour, C. 2005. Outcome and Long -Term Growth After 
Extensive Small Bowel Resection in the Neonatal Period: A Survey  of 87 Children. 
European Journal of Pediatric Surgery, 15, 95- 101.
Guarino, A.and De Marco, G. 2003. Natural History  of Intestinal Failure, Investigated Through a 
National Network -Based Approach. Journal of Pediatric Gastroenterology and Nutrition,
37, 136-141.
Jeppesen, P.B.and Mortensen, P. B. 2000. Intestinal failure defined by measurements of 
intestinal energy  and wet weight absorption. Gut, 46, 701-6.
Kelly , D. G., Tappenden, K. A.and Winkler, M. F. 2014. Short Bowel Syndrome: Highlights of 
Patient Management, Quality  of Life, and Survival. Journal of Parenteral and 
Enteral 
Nutrition, 38, 427-437.
Messing, B., 
Crenn, P., Beau, P., Boutron -Ruault, M. C., Rambaud, J. C.and Matuchansky , C. 
1999. Long-term survival and parenteral nutrition dependence in adult patients with the 
short bowel sy ndrome. Gastroenterology, 117, 1043-50.
Mughal, M.and Irving, M. 1986. Home parenteral nutrition in the United Kingdom and Ireland. 
Lancet, The, 2, 383-7.
Nightingale, J.and Woodward, J. M. 2006. Guidelines for management of patients with a short 
bowel. 
Gut, 55 Suppl 4, iv1 -12.
Nightingale, J. M. 1999. Management of patients with a short bowel. Nutrition, 15, 633-7.
O' Keefe, S. J., Buchman, A. L., Fishbein, T. M., Jeejeebhoy , K. N., Jeppesen, P. B.and Shaffer, 
J. 2006. Short bowel sy ndrom e and intestinal failure: consensus definitions and overview. 
Clin Gastroenterol Hepatol, 4, 6-10.
Pironi, L ., Arends, J., Bozzetti, F., Cuerda, C., Gillanders, L., Jeppesen, P. B., Joly , F., Kelly , D., 
Lal, S., Staun, M., Szczepanek, K., Van Gossum, A., Wanten, G.and Schneider, S. M. 
2016. ESPEN guidelines on chronic intestinal failure in adults. 
Clin Nutr, 35, 247-307.
Rombeau, J. L.and Rolandelli, R. H. 1987. Enteral and parenteral nutrition in patients with 
enteric fistulas and short bowel sy ndrome. Surg Clin North Am, 67, 551-71.
Shanbhogue, L. K.and Molenaar, J. C. 1994. Short bowel syndrome: metabolic and surgical 
management. Br J Surg, 81, 486-99.
For non-commercial use only
Shire CONFIDENTIAL Page 90
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
Vanderhoof, J. A.and Langnas, A. N. 1997. Short -bowel syndrome in children and adults. 
Gastroenterology, 113, 1767 -78.
Wales, P. W., de Silva, N., Kim, J., Lecce, L., To, T.and Moore, A. 2004. Neonatal short bowel 
syndrome: population -based estimates of incidence and mortality  rates. J Pediatr Surg,
39, 690-5.
Wilmore, D. W., By rne, T. A.and Persinger, R. L .1997. Short bowel sy ndrome: New therapeutic 
approaches. 
Current Problems in Surgery, 34, 389,391 -444.
For non-commercial use only
Shire CONFIDENTIAL Page 91
SHP681 -101 Protocol Am endment 4
GLP -2 analog -Fc fusion 19 Nov 2019
12. APPENDICES
Appendix 1 Protocol History
Document Date Global/Country/Site Specific
Original Protocol 29 Oct 2018 Global
Amendment 1 11 Feb 2019 Global
Amendment 2 10 May 2019 Global
Amendment 3 08 Oct 2019 Global
Amendment 4 19 Nov 2019 Global
For non-commercial use only